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Abstract 
 
Cell cycle entry requires a dramatic increase in protein production. In order to cope with 
this demand, the cell must upregulate ribosome biogenesis. Given that ribosome 
biogenesis is the most energy-consuming anabolic process in a growing cell, and that 
changes in cellular ribosome content can alter the genetic program, we hypothesized 
that control mechanisms must exist to synchronize ribosome biogenesis and cell cycle 
progression.  Here I report on a novel cell cycle checkpoint which is activated on the 
disruption of ribosome biogenesis and blocks cell cycle progression. Our studies, both 
in vitro and in vivo, show p21 and p53 as key mediators of this response. 
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Introduction  
The aim of this project is the identification of a putative checkpoint mechanism that 
regulates cell cycle progression with respect to ribosome biogenesis.  In the following 
sections, a brief description of the molecular mechanisms involved in the cell cycle, and 
its regulation, will be given. Particular emphasis will be placed on the mechanisms of 
regulation S phase entry. The subsequent sections will deal with the mechanisms of 
ribosome biogenesis and the regulation of this process during growth and proliferation 
in eukaryotic cells. Finally, a brief synopsis of the work already perfomed in this area of 
our lab will be provided, together with a description of the specific aims of my PhD 
project. 
 
The cell cycle 
The cell cycle represents the complete series of events from one cell division to the 
next. In eukaryotic cells this phenomenon can be divided in four major stages: G1, S, 
G2 and M. Each stage represents a different process undergone by the cell: The G1 
part of the cycle is generally associated with cell growth and the gathering of resources 
for DNA replication; during S phase the cell duplicates its DNA; and the G2 phase 
represents an interphase in which cells grow further in size, duplicate their cellular 
organelles and gather resources for mitosis. Finally, mitosis (M phase) is the process of 
DNA partitioning and physical cell division. Some cell types also undergo a G0 phase, 
a quiescent state preceding the G1 phase. 
  
A molecular overview 
 
The task of describing all the molecular events that characterize all these phases is 
beyond the scope of this introduction. Instead, I will concentrate on the mechanisms 
regulating G1 to S phase progression, on which my work has focused. Cyclins and 
cyclin-dependant kinases are known to be major players in mediating the progression 
and passage through these two phases of the cycle.  
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It is generally thought that stimuli in the form of mitogens can kick-start this response by 
inducing the phosphorylation of a class of proteins known as pocket proteins or Rb 
family of proteins (Lukas, Lukas et al. 2004). The pocket proteins have a role in 
maintaining inhibitory complexes on promoters of key cell cycle regulatory genes. 
Inhibition is mediated through the direct interaction with members of the E2F family of 
transcription factors and the recruitment of hystone acetylases to the promoter. Upon 
phosphorylation, the pocket proteins are released from this complex permitting E2F-
mediated transcription of the gene. A large number of genes that are regulated by E2F 
participate in cell cycle progression and the amplification of this process. Overall, these 
interactions constitute a positive feedback mechanism that allows the amplification of a 
mitogenic signal into a fully blown cellular response. The following sections describe 
the components of this pathway. 
  
Cyclins and cyclin-dependant kinases 
 
The phosphorylation of pocket proteins is mostly mediated by cyclin-dependent kinases 
(CDKs), a family of serine/threonine kinases. The activity and specificity of CDKs is 
modulated in a cell cycle-dependant manner by their association with cyclins. Cyclins 
are a group of structurally related proteins expressed during the different phases of the 
cell cycle. To date, at least 7 CDKs (1-7) and 8 major cyclin types (A-H) (Lew, Dulic et 
al. 1991) have been isolated from mammalian cells. Since each cyclin has a 
preferential CDK binding partner, the activity of each of the CDKs is controlled in a cell 
cycle-dependent manner. During late G1 phase, for example, cyclin E is actively 
expressed and binds CDK2, forming the cyclin E/CDK2 complex. Different cyclins can 
bind the same CDK albeit at different phases of the cell cycle: this phenomenon is best 
demonstrated by the recycling of CDK2 from cyclin E/CDK2 complexes into cyclin 
A/CDK2 complexes during S phase. Since cyclin A and cyclin E complexes share the 
same CDK but target different substrates (Nigg 1993), it implies that the substrate-
specificity of the associated CDK is at least partly conferred by the cyclin.  
In addition to their binding to cyclins, CDK activity is also regulated by the following 
mechanisms: phosphorylation of specific threonine residues by CDK-activating kinases 
(CAK) (Desai, Wessling et al. 1995); dephosphorylation of the Tyr 15- and Thr 14-
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conserved residues; and the presence of cyclin-dependent kinase inhibitors (CKI) such 
as p21. 
  
The composition of cyclin/CDK complexes with respect to the phases of the cell cycle is 
illustrated in (Fig.1). The major complex present in G1 is cyclin D/CDK(4,6), which is 
thought to be a molecular sensor that activates cell cycle progression in response to 
mitogenic stimuli (Sherr and Roberts 1999), but has also been associated with the 
regulation of cell growth (Sherr 1996). The initial phosphorylation of pocket proteins 
provided by this complex allows the transcription in the mid-to-late G1 of several genes 
involved in the cell cycle, of which cyclin E. Cyclin E complexes with CDK2 it promotes 
the phosphorylation of pocket proteins (Harbour, Luo et al. 1999), resulting in the 
release of inhibition of the rest of and the transcription of genes such  as cyclin A. In a 
mechanism similar to the one described for cyclin E, cyclin A further participates in the 
phosphorylation of the Rb proteins, allowing the expression of yet another set of 
proteins which are required for cell cycle progression. The dogma on the ordered 
fashion of these events has recently been challenged by mouse knockout experiments. 
In cyclin D-deficient fibroblasts, for example, proliferation is nearly normal even if the 
cells show an increased requirement for mitogenic stimulation. Similarly, fibroblasts 
lacking both CDK4 and CDK6 show a normal cell cycle progression, albeit with a less 
efficient entry into S phase (Malumbres, Sotillo et al. 2004). These results show that 
both cyclin D and its associated CDKs (4 and 6) are dispensable for cell cycle 
progression. Another set of studies using knockouts of both cyclin E subtypes (Geng, 
Yu et al. 2003) or CDK2 (Ortega, Prieto et al. 2003) show that neither E type cyclins 
nor CDK2 are strictly required for either embryonic development or for continuous cell 
cycle progression. These effects might be explained by a certain degree of target 
overlap between the different cyclins and CDKs and/or by the capacity of some of the 
cyclins to bind other CDKs. 
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Pocket proteins   
 
The Rb family of pocket proteins comprises three members: Rb; Rbl1/p107; and 
Rbl2/p130. All of these proteins are progressively phosphorylated during cell cycle 
progression, causing the release of inhibition on the E2F transcription factors.  
 
The Rb protein is mostly involved in the passage of cells from the G1 to the S state, 
while Rbl2 is more involved in the control of the release from the G0 phase (Garriga, 
Limon et al. 1998; Classon, Salama et al. 2000). The other member of this family, Rbl1, 
is transcriptionally upregulated during the middle of the G1 phase (Beijersbergen, 
Carlee et al. 1995): its transcription depends partly on E2F and therefore on the 
successful phosphorylation of Rb and/or Rbl2 (Zhu, Xie et al. 1995). With regards to 
their levels of expression, Rb protein levels are nearly constant throughout the cell 
cycle while levels of Rbl1 and Rbl2 are modulated in opposite manners (Beijersbergen, 
Carlee et al. 1995). Upon its full phosphorylation in the late G1/early S phase, Rbl2 is 
degraded while Rbl1 levels gradually increase. The inverse tendency is observed when, 
at end of mitosis, cells re-enter G0.  
 
The phosphorylation of pocket proteins is mostly mediated by CDKs and occurs at 
several sites, in a hierarchical manner. Recent data on Rbl2, for example, has shown 
the existence of 22 distinct phsophorylation sites, dependent on CDK(4,6) and/or CDK2 
Fig.1 Diagram 
depicting the 
different phases of 
the cell cycle, 
together with the 
major cyclin/CDK 
complexes involved 
in each phase. 
 
Page - 5  
 
 
(Farkas, Hansen et al. 2002). Some of the sites require the previous phosphorylation of 
other sites, suggesting that phosphorylation proceeds in an orderly manner. 
Furthermore, while some sites can be phosphorylated by either of the CDKs mentioned, 
some of them are solely dependant on CDK2 or CDK(4,6) (Farkas, Hansen et al. 2002). 
Due to the different timing of CDK(4,6) and CDK2 activity, phosphorylation of these 
sites reflects a cell phase-specific behavior. Similar observations have also been made 
for Rbl1 (Farkas, Hansen et al. 2002) . Interestingly, two phosphorylation sites on Rbl2 
are phosphorylated to as yet unidentified non-CDK kinases (Farkas, Hansen et al. 
2002). 
E2F transcription factors 
 
The E2F family of transcription factors is composed of at least seven members (E2F1-7) 
that physically associate to form a heterodimer with a member of the DP family (usually 
DP1), which subsequently binds to the E2F site in target genes. E2F transcription 
regulates a number of genes involved in cell proliferation and differentiation. Identified 
E2F target genes include cell cycle regulators such as cyclin E, cyclin A, Rbl1, cyclin 
D1, Cdc2, and Cdc25A, and enzymes involved in DNA synthesis and DNA replication 
such as dihydrofolate reductase (DHFR), DNA polymerase α, thymidine kinase, PCNA, 
Cdc6 and the minichromosome maintenance (MCM) proteins (Dyson 1998; Ren, Cam 
et al. 2002). Interestingly, some E2F members, such as E2F1, stimulate their own 
production and that of their binding partners, such as DP1 (Ren, Cam et al. 2002). This 
mechanism is responsible of the upregulation of E2F1 protein levels during the mid-to-
late S phase, which in turn stimulates the induction of further E2F-responsive genes 
and promotes S phase entry. 
 
E2F transcriptional activity is modulated by multiple mechanisms, including negative 
regulation by the Rb family of pocket proteins. Different E2F/DP complexes bind to 
different Rb proteins: E2F1, E2F2, and E2F3 preferentially associate with pRb (Dyson 
1998) and are potent transcriptional activators, whereas E2F4 and E2F5 predominantly 
interact with p107 and p130 and seem to be primarily involved in the active repression 
of E2F-responsive genes (Trimarchi and Lees 2002). E2F6 and E2F7 make up a 
subgroup that acts principally as a transcriptional repressor through a distinct pocket 
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protein-independent manner (Morkel, Wenkel et al. 1997; Di Stefano, Jensen et al. 
2003).  
 
The binding of pocket proteins to E2F members inhibits their transcriptional capacity, 
but also mediates the recruitment of acetylases (Brehm, Miska et al. 1998; Ferreira, 
Magnaghi-Jaulin et al. 1998) to the bound promoter, causing DNA conformational 
changes that further inhibit the transcription of the gene (O'Connor, Schaley et al. 2001). 
Since E2Fs constitute the docking sites for Rb proteins, their absence results in the 
disregulated activation of certain genes. Mice lacking E2F1, for example, have a higher 
propensity to develop tumors (Yamasaki, Bronson et al. 1998). Paradoxically, therefore, 
E2Fs can have a role both as oncogenes and tumor suppressors. 
 
Cyclin-dependent kinase inhibitors 
 
Cyclin-dependent kinase inhibitors are involved in the modulation of cyclin-dependant 
kinase activity during the cell cycle. This family of proteins can be divided in two broad 
categories: 
(i) Ink4: p16ink4a, p15ink4b, p18ink4c, p19ink4d 
(ii) CIP/Kip: p21CIP1/Waf1, p27Kip1, p57Kip2 
The members of the Ink4 group inhibit CDK4 and CDK6 by promoting their dissociation 
from cyclin D, while the CIP/Kip members inhibit all CDKs in a concentration-dependant 
manner (reviewed in (Sherr 1996)). Overexpression of any member of the CIP/Kip 
family causes a G1 block arrest in transfected cells (Pestell, Albanese et al. 1999), 
while overexpression of the Ink4 members such as p16 causes a reduction in the levels 
of the cyclin D/CDK4 complex (Hirai, Roussel et al. 1995; Quelle, Ashmun et al. 1995).  
 
The role of cyclin D/CDK4 in promoting cyclin E production through the phosphorylation 
of pocket proteins has already been described; an additional participation of the cyclin 
D/CDK4 complex in this process is the sequestration of p21 and p27 CKI (Sherr and 
Roberts 1995). The free p21 and p27 proteins present in the cell participate in the 
formation and stabilization of cyclin D/CDK4 complexes (LaBaer, Garrett et al. 1997; 
Cheng, Olivier et al. 1999). The titration of these two CKIs relieves the inhibition of 
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cyclin E/CDK2 complexes. This, in turn, grants the progressive accumulation of cyclin 
E/CDK2 activity and the further hyperphosphorylation of Rb proteins. This system 
generates a hierarchical program of CDK activation, since the increase in CDK2 activity 
during G1 requires the inactivation of both the CIP/Kip proteins and is therefore 
dependent on the prior activation of the cyclin D pathway. Once CDK2 becomes active, 
it triggers the degradation of p27 by targeting it for phosphorylation and subsequent 
ubiquitination (Vlach, Hennecke et al. 1997). This event has two major effects: the 
destabilization of cyclin D/CDK(4,6) complexes; and the resulting release of p21, which 
is now able to inhibit cyclin E/CDK2. The temporary titration of p21 by cyclin E/CDK2 
allows the formation of cyclinA/CDK2 complexes, which will then mediate S-phase 
progression. P21 and p27 differ mostly in their expression kinetics. Generally, p27 
levels are high in quiescent cells and decrease in late G1: the protein levels are thought 
to be regulated by proteosome mediated degradation (Vlach, Hennecke et al. 1997). 
P21 levels are, instead, low in quiescent cells and increase during the late G1 phase 
(Macleod, Sherry et al. 1995). In addition to its normal regulatory mechanisms, high 
p21 levels can be induced by the p53 pathway (el-Deiry, Tokino et al. 1993). The Ink4 
proteins are thought to mediate CDK activity modulation through the same pathway. 
Upon an anti-mitogenic stimulus, such as TGF-B, Ink4s are expressed and promote the 
dissociation of cyclin D/CDK4, which causes the releases of p21 and the inhibition of 
CDK2 activity (Reynisdottir, Polyak et al. 1995).  
 
Cell cycle checkpoints and the role of p53 
 
As described in the previous section, the progression through the cell cycle relies on an 
ordered series of events controlled by both activating and inhibitory interactions. The 
control of these mechanisms is of crucial importance for the development of 
multicellular organisms, where growth and division must be constrained. In this 
environment, cells proliferate only when subjected to stimuli such as growth factors and 
only when the integrity of the cell is not at stake. Cells have developed a number of 
“checkpoint” systems which are elicited to prevent cells from entering a new cell cycle 
phase before having completed the previous one, or when subject to a stress such as 
nutrient deprivation or UV damage. The most characterized of these checkpoints is the 
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so-called G1 “restriction point” (Pardee 1989). This checkpoint mechanism is placed 
the end of the G1 phase and constitutes a point of no return, after which cells are 
committed to enter S phase and duplicate their DNA. The molecular effectors of these 
checkpoint mechanisms are essentially the elements that participate in the normal cell 
cycle regulation: cyclins, CDKs, CDK inhibitors, and pocket proteins. Tumors constitute 
an example of a situation where these mechanisms have become defective, causing 
uncontrolled cell proliferation. Of particular interest in this manuscript is the role of the 
tumor suppressor p53, a frequent target of genetic alteration identified in human 
cancers (Hollstein, Sidransky et al. 1991).  
 
Stress signals from various pathways, such as DNA strand breaks, stalled DNA 
replication forks, ribonucleotide deprivation, and hypoxia, all appear to converge on the 
activation of p53, reviewed in (Ashcroft, Kubbutat et al. 1999). The most studied 
example is probably the induction of p53 by DNA damage. In order to prevent entry into 
S phase with damaged DNA, a checkpoint mechanism is triggered in G1 through the 
ATM/ATR and Chk1/Chk2 kinases. These transducing kinases activate two major 
responses: the phosphorylation of the Cdc25 proteins; and the activation of the p53 
transcription factor. The two mechanisms target, the same pathway but by two different 
means (Fig.2). 
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The phosphorylation of Cdc25a causes its degradation and decreases CDK2 activity 
which is dependant on the activatory dephosphorylation mediated by this protein (Zhao, 
Watkins et al. 2002; Sorensen, Syljuasen et al. 2003). The decrease in CDK2 activity 
affects the cyclin E/CDK2 and cyclin A/CDK2 complexes, which are not able to 
hyperphosphorylate the Rb pocket proteins. In the parallel pathway, p53 is activated by 
different mechanisms. Both the Chk1/2 kinases and ATM/ATR directly phosphorylate 
p53 and MDM2, a ubiquitin ligase that in its hypophosphorylated conformation targets 
p53 for degradation (Khosravi, Maya et al. 1999). The result is the activation and 
stabilization of p53 and the concomitant transcription of genes involved in cell cycle 
regulation and cell fate, such as p21CIP/Kip described earlier. p21 will also participate in 
the regulation of proliferation through the inhibition of CDK2 (Sherr and Roberts 
1999),.and the sequestration of PCNA, an essential component of the DNA replication 
machinery (Li, Waga et al. 1994). Altogether, these mechanisms block the cell in G1, 
allowing the activation of the DNA repair mechanisms. The block in the cell cycle is 
maintained mostly through p21 (Bartek and Lukas 2001) until the DNA has been 
repaired. In case of severe DNA damage, a p53-dependent pro-apoptotic pathway is 
stimulated through mediators such as PUMA, NOXA, BAX, and PIG3 (Vousden and Lu 
2002). p21 is actively degraded during the apoptotic response. This degradation is 
Fig.2 Pathways involved 
in the ATM/ATR-
mediated response to 
DNA damage (Lukas, 
Lukas et al. 2004). 
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considered to be one of the events pushing cells from stasis to apoptosis in response 
to DNA damage (Polyak, Waldman et al. 1996; Zhang, Fujita et al. 1999). P21 
therefore has a role in cell stasis and protects from p53-mediated apoptosis. 
 
To avoid the segregation of damaged DNA during mitosis the ATM/Chk(1,2) pathway 
also activates a block in G2. The mode of action is similar to the one just described for 
G1/S, but relies on the inhibition of CDK1, which normally associates with cyclin B and 
mediates progression from G2 to M. Cdc25c degradation by Chk1 phosphorylation 
(Brown, Lee et al. 1999), and p21 upregulation through p53, cause loss of CDK1 
activity. In addition, p53 also induces a number of other factors, such as 14-3-3σ, which 
anchors CDK1 in the cytoplasm where it cannot induce mitosis, and Gadd45, which 
dissociates CDK1 from cyclin B1 (Zhan, Antinore et al. 1999). All the mechanisms just 
described constitute just an example of how a cellular stress such as DNA damage can 
cause, through p53, the arrest of normal cell cycle progression.  
 
Ribosome biogenesis, the synthesis of new ribosomes 
 
Ribosome biogenesis is the process responsible for the synthesis of new ribosomes: it 
has been mostly characterized in yeast but is conserved in mammalian cells (Eichler 
and Craig 1994). In eukaryotes, ribosome biogenesis takes place in the nucleolus and 
involves the synchronized production of both ribosomal RNA (rRNA) and ribosomal 
proteins. The eukaryotic ribosome is composed of two subunits distinguished by their 
different sedimentation rate: the 40S or small ribosomal subunit; and the 60S or large 
ribosomal subunit. Both subunits are composed of an intricate assembly of rRNA and 
ribosomal proteins.  
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One of the major steps in ribsosome biogenesis is the synthesis of the rRNA. The 
ribosome is composed of four mature rRNAs: the 18S rRNA in the 40S subunit; and the 
5.8S, 28S, and 5S rRNAs in the 60S subunit. All, except the 5S, are derived from a 
same 45S rRNA precursor transcribed by RNA Pol I. The 45S rRNA precursor 
undergoes several processing steps to yield the mature rRNA (reviewed in (Fatica and 
Tollervey 2002)). The cleavage of the A2 site is of particular relevance, since it 
corresponds to the separation of the precursor of the 18S rRNA from that of the 
28S/5.8S rRNA (Fig.3). Following this cleavage, the two rRNAs are extensively 
modified, a process requiring both endo- and exonucleases and the binding of 
ribosomal proteins. The 5S rRNA is transcribed separately by RNA polymerase III (Pol 
III) and does not undergo further processing. Ribosomal proteins, which bind to the 
rRNA, are transcribed by RNA polymerase II (Pol II). They are produced in the 
cytoplasm and then imported into the nucleus or nucleolus for assembly with the rRNA. 
Ribosome biogenesis therefore requires the coordination of events in different cellular 
compartments and the transcriptional activity of different polymerases. In mammalian 
cells, the means used for this coordination are still largely unknown.  
  
 
Fig.3. rRNA processing 
pathway in Saccharomyces 
cerevisiae (Fatica and 
Tollervey 2002). 
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Ribosome biogenesis during cell growth and cell proliferation  
 
Cell growth and cell proliferation require that cells adjust their protein biosynthetic 
capacity in response to nutrient availability and external stimuli such as mitogens or 
growth factors. This involves coordinated changes both in the rate of translational 
initiation and in the abundance of the protein synthesis machinery itself, especially the 
number of ribosomes. Studies in both prokaryotic and eukaryotic cells have shown that 
the concentration of ribosomes within the cell can vary several-fold depending on 
growth rate (reviewed in (Gausing 1974; Woolford 1991)). Coordination between 
ribosome biogenesis and cell state is probably derived from the phase-specific 
requirements of ribosome numbers to meet demands for protein biosynthesis, but also 
from a need to preserve energy resources, since ribosome biogenesis requires a large 
amount of energy expenditure. It has been estimated that ribosome biogenesis 
constitutes 80% of the work of cell proliferation (Sollner-Webb and Tower 1986), and in 
Saccharomyces cerevisiae it consumes an extraordinary proportion of the cell's 
resources, accounting for >70% of all transcription (about 50% of all Pol II transcription) 
(Warner, Vilardell et al. 2001). 
 
Ribosome biogenesis is a very complex process and can be regulated at different 
levels. It has been known for a long time, for example, that Pol I-mediated transcription 
of rRNA is tightly controlled. Amino acid starvation and nucleotide levels affects rRNA 
transcription rates (Grummt and Grummt 1976; Grummt, Smith et al. 1976), 
accomomodating rRNA production to the availability of nutrients and therefore to the 
rate of growth. From a cell cycle perspective, the rate of rRNA gene transcription 
decreases markedly in cells that are in S phase, whereas it becomes upregulated upon 
treatment with mitogenic signals. The primary transcription factor involved in the cell 
cycle-dependent regulation of rRNA transcription is TIF-IA which, together with UBF, 
controls the activity of Pol I (Schnapp, Pfleiderer et al. 1990; Jacob 1995; Datta, 
Budhiraja et al. 1997). Part of the effect of members of the pocket protein family on cell 
cycle progression is probably due to their effects on Pol I transcription. In fact, Rb and 
Rbl2 have been reported to inhibit the activity of Pol I through binding to its enhancer, 
UBF. Consistent with a role of pocket proteins in the inhibition of Pol I, rRNA synthesis 
is elevated in fibroblasts lacking both Rb and p130 (Ciarmatori, Scott et al. 2001). 
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Furthermore, all the members of the Rb pocket protein family are able to interact with 
and inhibit Pol III activity (Sutcliffe, Cairns et al. 1999), which is responsible for the 
synthesis of tRNA and the 5S rRNA, which are necessary for translation and ribosome 
biogenesis respectively. Given the regulation of pocket proteins during the cell cycle, 
these interactions have probably evolved to modulate ribosome biogenesis as a 
function of cell cycle progression. Interestingly, p53 has also been shown to inhibit Pol I 
transcription, providing a mechanism to downregulate ribosome biogenesis during 
stress responses (Budde and Grummt 1999). In certain cell types, ribosome biogenesis 
is also regulated at the post-transcriptional level. During rRNA processing, as much as 
half of 18S rRNA can be degraded continuously in resting cells: this process is 
attenuated when cells receive growth stimuli (Cooper and Gibson 1971; Dudov and 
Dabeva 1983; Eichler and Craig 1994). 
The regulatory mechanisms described so far rely on rRNA synthesis and availability. 
Importantly, efficient assembly of ribosomes requires coordination in the synthesis of 
their main components, rRNA and ribosomal proteins. In metazoa, the production of 
ribosomal proteins is regulated mainly at the translational level (Meyuhas, Nir et al. 
1996; Thomas 2002). The transcripts encoding for ribosomal proteins are poorly 
translated in resting cells, whereas they are efficiently recruited to translating ribosomes 
when cells are exposed to growth and mitogenic signals. Translational regulation is 
conferred on these mRNAs by the presence of an unusual pyrimidine-rich sequence at 
their 5' end, referred to as a 5'-TOP (5'-Terminal OligoPyrimidine) tract. Regulation of 
5’-TOP messages is mediated by the mTOR pathway, possibly through the activation of 
S6K (Meyuhas, Nir et al. 1996; Jefferies, Fumagalli et al. 1997). It is interesting that 
mTOR activity also stimulates the transcription of rRNA, possibly ensuring a certain 
degree of temporal coordination between production of rRNA and ribosomal proteins. 
mTOR appears to function as a hub, receiving input from mitogens, growth factors, 
nutrients, and energy levels (Zhang, Stallock et al. 2000; Dennis, Jaeschke et al. 2001; 
Shamji, Nghiem et al. 2003). It therefore constitutes an ideal gatekeeper for the 
regulation of ribosome biogenesis in response to the environment which the cell is 
exposed to. There is also evidence that the Rbl1 pocket proteins take advantage of this 
pathway to mediate a cell cycle-dependent inhibition of ribosomal protein synthesis, 
supported by the observation that overexpression of Rbl1 leads to the downregulation 
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of ribosomal protein translation, in correlation with a loss of S6 phosphorylation, a main 
substrate of S6K (Makris, Voisin et al. 2002). 
 
Regulation of cell growth and cell proliferation by ribosome 
biogenesis 
 
The previous section has highlighted the mechanisms that control ribosome biogenesis 
in response to cell growth and proliferation. Is there also a mechanism that controls cell 
growth and cell proliferation in response to ribosome availability or translation capacity? 
We hypothesize that such a mechanism exists for the following reasons:  
 
(1) A feedback mechanism should exist in order, for example, to communicate to 
the cell cycle machinery to halt the upregulation of ribosome biogenesis when 
the required protein synthesis rate has been achieved, avoiding in this way 
unnecessary energy expenditures.  
(2) The failure to upregulate ribosome biogenesis, in case of a defect, would create 
an imbalance in the number of ribosomes, potentially resulting in alterations to 
the translational program. It is thought that in mammalian cells mRNAs compete 
for association with ribosomes which are thought to be present in limiting 
amounts (Lodish 1974). The complexity of the 5’ UTR of the mRNAs, their 
relative abundance, and their affinity for the translational machinery influences 
their rate of translation. Variations in ribosome amounts may lead to alterations 
in the pattern of the translated mRNA and have deleterious effects on cell 
homeostasis.   
 
My project aimed at determining whether such control mechanisms exist. The 
publication by Volarevic et al. (Volarevic, Stewart et al. 2000) presents work previously 
performed in our laboratory on this subject. My PhD. project stemmed directly from this 
work.  
 
The work by Volarevic et al. describes the generation of mice harboring a conditional 
deletion of the gene encoding the S6 ribosomal protein, a member of the 40S 
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ribosomal subunit. Deletion of S6 in adult mouse livers causes the abrogation of 40S 
synthesis due to a defect in the processing of the 18S rRNA precursor. The deletion of 
the S6 gene stops 40S ribosome biogenesis whithout affecting the pre-existing pool of 
ribosomes. Global translation was also shown to be unaltered by this defect.  
 
To test the effects of the lack of ribosome biogenesis on cell growth and on cell 
proliferation, the livers were subjected to a starvation/refeeding experiment and to 
partial hepatectomy, respectively. The starvation/refeeding experimental paradigm 
relies on the fact that, when a mouse is starved of nutrients, the size of its liver 
decreases. Upon refeeding, however, the liver grows back to its original size, a process 
that relies solely on cell growth. Upon starvation and subsequent refeeding, ΔS6 livers 
grew back to their original size, showing that abrogation of ribosome biogenesis by S6 
deletion does not affect liver growth under these conditions. The hepatectomy 
experiment, instead, is based on the property of the liver to regenerate to its original 
size after the removal of 70% of its mass. Regeneration relies principally on 
proliferation. When subjected to hepatectomy, ΔS6 livers failed to regenerate, showing 
that in the absence of ribosome biogenesis proliferation is compromised (Fig.4A).  
 
A more detailed molecular characterization revealed that the G1 phase was unaltered 
in cells from ΔS6 livers, as shown by the normal kinetics of downregulation of p27 and 
accumulation of p21 and cyclin D protein levels. Furthermore, the activity of the 
cyclinD/CDK4 was normally induced, as in wild-type livers (Fig.4B). On the other hand, 
cells lacking S6 failed to progress through S phase and showed a lack of cyclin E, both 
at the protein and transcripts level, and as a consequence of CDK2 activity (Fig.4C). 
Altogether, these findings suggested the existence of a mechanismthat stops cell 
proliferation in response to defects in ribosome biogenesis (Fig.5). 
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Fig.5 Model of the relationship between ribosome biogenesis and the 
cell cycle. In a wildtype situation, ribosome biogenesis is triggered by 
the cell cycle machinery and participates in cell cycle progression. In 
case of a defect in ribosome biogenesis, a checkpoint mechanism is 
activated upstream of cyclin E, and prevents cell cycle progression. 
Fig.4 (A) Wildtype and ΔS6 livers 10 days after hepatectomy. (B) 
Characterization of G1-phase proteins at different timepoints after 
hepatectomy in wt and ΔS6 livers. (C) Characterization of S-phase 
proteins at different timepoints after hepatectomy in wt and ΔS6 
livers. 
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Aims of the PhD project 
o (1) To determine the origin of the mechanisms that cause the cell 
cycle block in cells defective in ribosome biogenesis 
The uncovering of such mechanism will provide clues on how ribosome biogenesis 
interacts with the cell cycle machinery. 
o (2) To establish an in vitro system that mimics the effetcs of deletion 
of the S6 gene in the mouse 
The aim is to gain experimental flexibility by using an in vitro model that can be more 
easily manipulated than the current mouse model and allows the testing of whether the 
phenotype observd in vivo is cell-autonomous. 
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Results 
Characterization of a cell cycle checkpoint induced by the conditional 
deletion of the ribosomal protein S6 in the liver 
o Characterization of the checkpoint by microarray analysis 
 
Previous studies from our lab have shown that mouse livers harboring a conditional 
deletion of the S6 ribosomal protein (S6) gene are not able to regenerate in response 
to hepatectomy (Volarevic, Stewart et al. 2000), due to the failure of the hepatocytes to 
enter the first S phase. The absence of cyclin E induction, both at the protein and RNA 
levels, was thought to contribute to the defect in proliferation, although the involvement 
of additional lesions could not be excluded. Therefore, in order to gain a wider view of 
the genes and pathways possibly involved in the cell cycle block elicited by S6 
depletion, I performed a microarray analysis using chips from Affymetrix. With this 
approach it was possible to measure the expression at the mRNA level of several 
thousand genes simultaneously. For this purpose I collected samples at different times 
following partial hepatectomy. Two types of mice were used: (1) mutant mice harboring 
a floxed version of the S6 gene and transgenic for a CRE recombinase under the 
control of the Mx promoter (Mx-Cre), where deletion was triggered through injection of 
polyI:polyC (I will refer to these mice as ΔS6/flox); and (2) wildtype mice harboring the 
floxed S6 gene, lacking the Mx-Cre transgene, and also injected with polyI:polyC (I will 
refer to these mice as S6/flox). Remnants of the livers were collected at: 0, 20, 30, and 
40 hours after a two-thirds hepatectomy. The first S phase in this genetic background 
occurs about 40 hours after hepatectomy (Volarevic, Stewart et al. 2000). We used 
three mice per timepoint per genotype.  
 
In order to determine the differences in gene expression between S6/flox and ΔS6/flox 
livers, I compared the two genotypes at each timepoint and derived a list of 
differentially expressed genes. I selected genes showing at least a 1.5-fold change 
between the two genotypes at any given phenotype and showing a change p-value of 
<0.01. These settings chosen for the fold change are slightly less stringent than the 
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arbitrary 2-fold change limit routinely used by other groups. The results, however, show 
that even slight changes in mRNA levels can cause substantial differences in protein 
levels. Decreasing the stringency in the fold change resulted in a substantial increase 
in candidate genes. Taking advantage of the fact that we had three replicates for each 
condition, I compensated this increase with a more stringent filter on the p-value 
change (less than 0.01 rather than 0.05). Because of the higher stringency in the 
analysis, this approach was aimed at obtaining a list of the best candidate genes rather 
than a comprehensive list of all the genes changing between the two genotypes (the 
results of the analysis are listed in Appendix A). As a proof of concept, we first 
measured the S6 mRNA levels in the samples (Fig.6). As expected, in the liver of 
ΔS6/flox mice the expression of the S6 transcript remained below detectable levels 
throughout the time course of the experiment, showing the efficiency of the conditional 
knockout. 
 
 
As shown in (Fig.7), the number of genes differentially expressed increased as a 
function of time, with a sharp increase at 30 hours after hepatectomy. A more accurate 
analysis showed that the majority of genes collected in the lists were more expressed 
in S6/flox livers. These differences could be caused either by the induction of these 
genes in S6/flox livers and/or by their downregulation in the ΔS6/flox condition. 
 
Fig.6 Normalized microarray 
data of the expression levels of 
S6 ribosomal protein in S6/flox 
(blue) versus ΔS6/flox (red) at 
different timepoints after 
hepatectomy. Each data point 
represents the average of 
three independent 
experiments. Error bars 
correspond to standard error.  
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In order to clarify this point I performed an expression cluster analysis to identify genes 
displaying differences in expression between the two genotypes throughout the time 
course. I initially focused on the list of genes differentially expressed at 40 hours, for 
two reasons: first, at this timepoint I observed the highest number of differences 
between the two genotypes; and second, it is at 40 hours that the differences, with 
regards to entry into S phase, were originally detected between the two genotypes. The 
cluster analysis showed that in the liver of S6/flox the expression of a number of genes 
increased with time, reaching a peak at 40 hours after hepatectomy. Those same 
genes were not induced in the liver of ΔS6/flox (Fig.8A). On the other hand, the 
analysis of other timepoints led to the identification of genes expressed at higher levels 
in ΔS6/flox. In particular, expression of these genes was induced in both genotypes at 
20 hours, although to a higher extent in ΔS6/flox. Furthermore, whereas in ΔS6/flox 
expression of these genes was maintained, it was instead gradually attenuated in 
S6/flox mice throughout the rest of the time course (Fig.8B). We decided to study these 
two major clusters in more detail by analyzing the genes that composed them. The 
following sections of this manuscript deal with this analysis. 
 
Fig.7 Histogram showing the 
number of genes found 
differentially expressed 
between S6/flox and ΔS6/flox 
at different timepoints after 
hepatectomy. Each bar is 
divided into genes expressed 
more in S6/flox or ΔS6/flox.  
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o Lack of upregulation of cell cycle inducer genes in ΔS6/flox livers 
 
I first analyzed the cluster of genes more expressed in S6/flox. As previously 
mentioned, these genes fail to be upregulated in ΔS6/flox. Since the over-
representation of genes from a common functional class within an expression cluster 
can reveal a global pathway of activation, we grouped these genes by their biological 
function using the “Affymetrix GO analysis tool” (http://www.affymetrix.com) and 
“FatiGO” (Al-Shahrour, Diaz-Uriarte et al. 2004). The analysis resulted in the 
identification of several functional categories (Fig.9). Since I was principally interested 
in the mechanisms that control the cell cycle, I decided to focus the categories that 
could be directly linked to this process. Interestingly, I found that about 68% of the 
genes clustered in functional categories such as “cell proliferation”, “DNA metabolism”, 
and “regulation of nucleotide and nucleoside biosynthesis”, which are directly involved 
in cell cycle progression. The genes found in these three categories were pulled 
together into a unique group referred to hereafter as CCIND (Cell Cycle Induced 
genes).  
 
Fig.8 Expression cluster analysis of genes differentially expressed between S6/flox and 
ΔS6/flox at 40 hours after hepatectomy. Two distinct clusters are shown: (A) genes expressed 
more in S6/flox; and (B) genes expressed more in ΔS6/flox. Each horizontal line corresponds 
to a gene. Each column represents a timepoint. The colors reflect the levels of expression. 
Page - 23  
 
 
 
 
 
The 
CCI
ND 
list 
repr
ese
nts 
gen
es 
with 
a 
similar expression profile and a related function. We set out to determine whether these 
genes shared common regulatory pathways. We found that about 49% of the CCIND 
gene promoters had peviously been reported to interact with E2F (Ren, Cam et al. 
2002) (Fig.10). 
 
o E
2
F
1
 
cell proliferation 
Brrn Anln Aurkb Brca1 Bub1 Ccna2 Ccnb2  
Cdc20 Cdc6 Cdkn3 Cks1 Fen1 H2afx Mad2l1 Mcm5 
Nek2 Plk1 Plk4 Rbl1 Ris2 Rrm1 Rrm2 Stk6 
Tacc3 Top2a Uhrf1 
DNA metabolism 
Aurkb  Brca1  Cbx5  Cenpa  Ezh2  Fen1  H2afx  H2afz  
H2av  Hat1  Hmgb1 Hmgb2  Mcm5  Rad51ap1  Rrm1 
Rrm2  Tk1 Top2a   
cell organization and biogenesis 
Cbx5 Cenpa  Ezh2  H2afx  H2afz  H2av  Kif22  Rps6  
Tuba1  Tuba2  Tuba6 
transport 
Fabp1  Hba-a1 Hbb-b1  Hmgb1  Sec61b Tacc3  Tuba1  Tuba2  
Tuba6 Uhrf1   
protein modification 
2700084L22Rik  Aurkb  Bub1 Ezh2  Hat1  Nek2 Plk1 
Plk4  Stk6 
regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism 
Atpi Ezh2  Hmgb2  Mcm5  Pbx3  Rbl1  Tcf19  Tmpo  
Uhrf1 
transcription Ezh2  Hmgb2  Mcm5  Pbx3  Rbl1  Tcf19 Tmpo  Uhrf1 
phosphate metabolism Aurkb  Bub1 Nek2 Plk1 Plk4  Stk6 
CCIND genes E2F regulated Aurkb       Brca1       Bub1       Ccna2       Cdc20     Cdc6       Cks1     Ezh2         
Fen1 Mad2l1     Mcm5     Rbl1           Rrm1      Rrm2       Top2a   H2afx 
Tk1 
Other CCIND genes Anln Atpi     Brrn   Cbx5      Ccnb2     Cdkn3      Hat1     Hmgb2  
Hmgb1  Nek2 Pbx3  Plk1 Plk4         Ris2         Stk6     Rad51ap1 
Tacc3 Tcf19  Tmpo  Uhrf1 
Fig.9 Functional analysis, using gene otology, of genes expressed more in S6/flox at 40 hours 
after he patectomy. The top panel represents the percentage of genes present in each 
category. Categories representing less than 5% of the genes were not considered. The bottom 
panel lists the genes in each corresponding functional category. Each gene can have multiple 
functions and is therefore likely to be found in more than one category. The genes 
represented in blue constitute the list of selected CCIND genes. 
Fig.10 Table listing the cell cycle induced genes (CCIND) selected from the expression and functional 
clustering .The genes are divided according to whether they have been reported to depend on E2F 
transcription or not. Although other transcription factors are involved in the regulation of these genes, 
none were represented at to the same extent as E2F. 
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target genes are not induced in ΔS6/flox hepatocytes after 
hepatectomy 
The E2F family of transcription factors comprises 7 members, all involved in both the 
positive and negative regulation of cell proliferation and differentiation. E2F1, in 
particular, has been characterized as a major inducer of cell proliferation (Chellappan, 
Hiebert et al. 1991) by mediating the transcription of several genes involved in DNA 
replication. E2F1 expression is regulated transcriptionally and peaks at the onset of S 
phase (Slansky, Li et al. 1993). I was therefore surprised by the absence of E2F1 in the 
list of differentially expressed genes. A closer look at the microarray raw data revealed 
that at 40 hours after hepatectomy E2F1 showed a p-value difference of 0.0057 
between the two genotypes, a value well within the 0.01 threshold used. The gene, 
however, showed an overall fold change of expression between the two genotypes of 
1.49, just below the 1.5 threshold set in our initial analysis, explaining why it was not 
found within our final gene lists (Fig.11A). It is important to note that a fold change 
threshold, as set in our experiment, is a purely arbitrary value, since even slight 
changes in the expression of a gene can greatly affect its protein levels. Using northern 
blot analysis we showed that E2F1 mRNA was undetectable in ΔS6/flox at all the 
tested timepoints, whereas it was indeed gradually induced in S6/flox, reaching its 
maximum at 40 hours (Fig.11B). 
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On the base of this result, I hypothesized that a defect in E2F1 expression could 
explain the lack of induction of some of the CCIND genes in ΔS6/flox. To test this 
hypothesis further, I measured the levels of E2F1 protein. I was, however, unable to 
detect it through either western blotting or in vitro DNA pull-down assays, probably 
because of the relatively low abundance of this transcription factor in the liver. I 
therefore used the levels of Rbl1/p107 protein as readout for E2F1 activity. Rbl1 
belongs to the pocket protein family of proteins that also includes Rb and Rbl2/p130. 
Rbl1 has been described as an E2F1 target and is upregulated in a cell cycle-
dependent manner (Beijersbergen, Carlee et al. 1995; Hurford, Cobrinik et al. 1997). 
However, in contrast to other E2F targets present in our list, Rbl1 has been shown to 
be already upregulated in mid G1, rather than at the G1/S boundary, providing an 
earlier readout for E2F1 activity (Bartek, Bartkova et al. 1997). Consistent with these 
data, I observed the transcriptional upregulation of Rbl1 at 20 hours after hepatectomy 
in S6/flox. ΔS6/flox livers showed instead a complete lack of Rbl1 upregulation both at 
Fig.11 (A) Normalized microarray data of the expression levels of E2F1 in 
S6/flox (blue) versus ΔS6/flox (red) at different timepoints after hepatectomy. 
Each data point represents the average of three independent experiments. 
Error bars correspond to standard error. (B) Northern blot showing E2F1 
mRNA levels in S6/flox and ΔS6/flox livers at different timepoints after 
hepatectomy. 
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the RNA and at a protein level (Fig.12), providing evidence for a lack of E2F1-regulated 
transcription in this genotype. 
 
 
o Rbl2 remains hypophosphorylated in ΔS6/flox livers 
 
In cells entering the cell cycle, the upregulation of E2F1 relies on an auto-regulatory 
feed forward mechanism, where E2F1 induced its own expression through the binding 
of its own promoter (Johnson, Ohtani et al. 1994). This mechanism is based on the 
presence of an initial small pool of E2F1 protein and on the release of complexes 
containing pocket proteins that bind the promoter of E2F-responsive genes and actively 
repress their transcription (Johnson, Ohtani et al. 1994). The release of these inhibitory 
complexes is mediated by the phosphorylation of the pocket proteins from cyclin-
dependent kinases (Cdks) and is a prerequisite for E2F1-mediated transcriptional 
Fig.12 (A) Normalized microarray data of the expression levels of 
Rbl1/p107 in S6/flox (blue) versus ΔS6/flox (red) at different timepoints 
after hepatectomy. Each data point represents the average of three 
independent experiments. Error bars correspond to standard error. (B) 
Western blot showing Rbl1/p107 protein levels in S6/flox ΔS6/flox livers at 
different timepoints after hepatectomy. 
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activation. Given the lack of E2F induction in ΔS6/flox, we tested the state of the pocket 
protein inhibitory complexes. In particular, we focused on Rbl2/p130 which, in a 
complex with E2F4, is known to mediate inhibition of transcription of E2F targets in 
resting livers (Garriga, Limon et al. 1998). Mitogenic stimuli trigger the release of the 
Rbl2/E2F4 inhibitory complex, through phosphorylation of Rbl1 and entry of the cells 
into G1 (Mayol, Garriga et al. 1995). We therefore decided to measure the levels of 
Rbl2 and its phosphorylation status during cell cycle progression. Using western 
blotting with an anti-p130-specific antibody we detected a slower migrating band, 
indicative of phosphorylation (Garriga, Limon et al. 1998), at 30 and 40 hours post 
hepatectomy, in extracts from livers of S6/flox but not in ΔS6/flox, suggesting a lack of 
Rbl2 phosphorylation in the livers of the latter.  
 
Rbl2 has been reported to harbor 20 potential phosphorylation sites (Farkas, Hansen et 
al. 2002) and not all of them contribute to a detectable bandshift on a western blot. We 
therefore complemented this experiment with a more functional evaluation using 
electromobility-shift assays (EMSA). This assay measures the binding of protein 
complexes to a radioactively labeled oligonucleotide containing the E2F consensus-
binding motif. It has been shown that, in resting livers, Rbl2/E2F4 complexes constitute 
the main binding activity to such an oligonucleotide (Garriga, Limon et al. 1998). These 
data were confirmed in our experiments, as shown in (Fig.13B). Incubation of the 
radiolabelled oligonucleotide with nuclear extracts from resting ΔS6/flox livers resulted 
in its upward shift, detectable through PAGE (Fig.13B, lane 2). The binding was 
competed by an excess of cold oligonucleotide, indicating the specificity of the 
interaction (Fig.13B, lane 3) and furthermore the presence of Rbl2 in the complex 
bound to the oligonucleotide was confirmed by the supershift obtained after pre-
incubation with an anti-Rbl2 antibody (Fig.13B, lane 5). Using the same assay, we then 
analyzed the binding activity at different timepoints after hepatectomy for both S6/flox 
and ΔS6/flox. At 0 hours, binding of Rbl2/E2F4 complexes was detected for both 
ΔS6/flox and S6/flox. After hepatectomy, binding activity was gradually lost in S6/flox, 
as cells progressed into the cell cycle (Fig.13D) and in parallel with an increase in Rbl1 
expression (Fig.13C). In ΔS6/flox, instead, at all timepoints analyzed the binding of 
Rbl2/E2F4 was indistinguishable from the one detected in resting liver. Altogether, 
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these experiments show that in ΔS6/flox livers, Rbl2 fails to be phosphorylated 
following hepatectomy: it remains in its DNA-bound conformation, therefore repressing 
the expression of the E2F target genes. 
 
o Cell cycle inhibitory genes are induced in ΔS6/flox livers 
 
As previously shown in (Fig.8), we also identified a second expression cluster, 
composed of genes which are expressed more in ΔS6/flox. In contrast to the CCIND, 
these genes are upregulated in both genotypes at 20 hours after hepatectomy, 
although at higher levels in ΔS6/flox livers. Furthermore, at subsequent timepoints, 
their expression is maintained at higher levels in ΔS6/flox livers, whereas it decreases 
in S6/flox livers. Because of these differences, we devised an alternative approach to 
Fig.13 (A) Western blot showing Rbl2 levels in S6/flox  and ΔS6/flox at different timepoints 
after hepatectomy. (B) Electromobility shift assay to test specificity of binding and detection of 
Rbl2: Lane1 E2 probe only (negative control); Lane2 E2 probe + Time 0 S6/flox (positive 
control); Lane3 competition with wt cold probe (50-fold excess; Lane4 competition with 
mismatched cold probe (50-fold excess); Lane5 supershift with anti-Rbl2 Ab; Lane6 supershift 
with anti-Rb Ab. (C) Western blot showing Rbl1 levels in S6/flox  and ΔS6/flox at different 
timepoints after hepatectomy. (D) Electromobility shift assay to test the binding activity of the 
Rbl2 complex in S6/flox  and ΔS6/flox at different timepoints after hepatectomy 
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uncover candidate genes involved in the cell cycle block. We formed a list of genes that 
in our experiment were expressed more in ΔS6/flox at at least two different timepoints, 
since we reasoned that their differential expression over a longer time range could 
have an impact on the phenotype observed (Fig.14). 
 
Among the genes identified with such properties, Cdkn1a was of particular interest. 
This gene, also known as p21, codes for a cyclin-dependent kinase inhibitor known to 
affect cell cycle progression (Harper, Adami et al. 1993). P21 mRNA levels were 
already about four times higher in the liver of ΔS6/flox when compared to S6/flox at 
time 0, i.e. before the start of the regenerative response. The levels of p21 transcript 
increased steadily until 30 hours after hepatectomy in ΔS6/flox, whereas in S6/flox they 
peaked at 20 hours after hepatectomy and decreased at the subsequent timepoints. 
The p21 protein levels reflected the kinetics observed in the microarray data. In S6/flox, 
p21 protein levels increased after hepatectomy, as previously reported by other groups 
(Albrecht, Poon et al. 1998). In ΔS6/flox the levels of the p21 protein were higher than 
in S6/flox throughout the timecourse, except at 40 hours where, interestingly, p21 
expression dropped to levels equivalent to S6/flox (Fig.15).  
 
Fig.14 List of genes derived from microarray analysis that show an upregulation in ΔS6/flox at 
more than one of the timepoints collected. The genes selected show a fold change of >=1.5 
and a change p-value of <0.01. The timepoints at which these genes show a significant 
differential expression are reported in the last column, together with the respective fold change 
and change p-value 
GeneSymbol FoldChange ChangePValue Time (Hours) Function
1.70 5.30204E-05 30
1.52 0.002868942 40
1.86 0.007473629 0
1.58 0.00135573 20
1.93 0.002101344 30
1.81 0.004325134 40
3.87 0.00102304 0
5.12 0.005218889 30
1.93 0.007452688 30
2.00 0.007547999 40
1.50 0.00961459 0
2.39 0.000403408 30
3.42 6.66179E-05 40
1.81 0.00138372 0
1.62 0.006381256 30
4.54 0.000704678 30
4.69 0.001954447 40
1.83 0.003219623 0
2.29 0.009590066 20
2.01 0.001044018 40
Phlda3
---
 induction of apoptosis by intracellular signals
ribosome biogenesis
regulation of cell cycle 
---
 regulation of translational initiation
proteolysis and peptidolysis
differentiation
signal transduction
E130105L11Rik
Eif5
Ephx1
Ifrd1
Brix
2610318G08Rik
Bax
Cdkn1a
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In many systems, transcription of p21 is known to be mediated by p53. We were 
therefore intrigued by the presence of Bax in the list, a well-known target of p53 
(Miyashita and Reed 1995; Tang, Zhao et al. 1998). Given the involvement of p53 in a 
multitude of cellular checkpoints and its role in cell cycle regulation (Kuerbitz, Plunkett 
et al. 1992), I assessed whether other p53-targeted genes were differentially expressed. 
In addition to p21 and Bax, we found that the levels of Gadd45γ, cyclin G and Mdm2 
mRNA were upregulated in ΔS6/flox at at least one of the timepoints, with a fold 
change of >1.5 and a change p-value of <0.05 (Fig.16). These results suggested a 
possible role of p21 and/or the p53 pathway in the ΔS6/flox S-phase block. 
Fig.15 (A) Normalized microarray data of the expression levels of 
Cdkn1a/p21 in S6/flox (blue) versus ΔS6/flox (red) at different timepoints 
after hepatectomy. Each data point represents the average of three 
independent experiments. Error bars correspond to standard error. (B) 
Western blot showing Cdkn1a/p21 protein levels in S6/flox ΔS6/flox livers at 
different time points after hepatectomy 
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o Deletion of S6 is sensed before hepatectomy 
 
Surprisingly even at time 0 the levels of p21 were higher in ΔS6/flox livers. The sample 
collected at time 0 corresponds to the piece of liver removed during the hepatectomy 
and is therefore subject to surgical stress. To exclude the possibility of p21 levels rising 
in response to the surgical procedure, I collected livers from ΔS6/flox mice in the 
absence of any manipulation (timepoint –1 hour) and measured the levels of p21. Even 
before any surgical procedure, p21 levels were higher in ΔS6/flox livers (Fig.17A). 
 
In order discard the possibility that p21 is upregulated because of the different genetic 
background of these mice (ΔS6/flox mice contain an Mx-Cre transgene), I collected 
liver samples from ΔS6/flox Mx-Cre- and S6/flox Mx-Cre+ mice before the induction of 
the S6 excision (timepoint –72 hours). Using microarray analysis, I compared the 
samples derived from the –72 and –1 timepoints. At –72 hours the levels of p21 were 
identical in the two genotypes (Fig.17B). Upon deletion of S6, but before any surgical 
procedure, p21 levels rose in ΔS6/flox livers. In addition to a rise in p21 levels, livers 
Fig.16 Normalized microarray data of the expression levels of p53 targets: Bax, cyclin G, 
Mdm2 and IGFBP3, at different timepoints after hepatectomy. Genotypes are expressed with 
different colors S6/flox (blue), ΔS6/flox (red). Each data point represents the average of three 
independent experiments. Error bars correspond to standard error 
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collected before surgery showed the presence of the 34S rRNA precursor (Fig.17C), 
which is indicative of a defective ribosome biogenesis caused by S6 deletion (Volarevic, 
Stewart et al. 2000). From this data I conclude that even before hepatectomy ΔS6/flox 
livers show a defect in ribosome biogenesis and an increased level of p21.  
Fig.17 (A) Expression levels of p21 mRNA in S6/flox and ΔS6/flox liver before surgery (T-1) 
and beginning of surgery (T0). (B) Graph showing the microarray expression data of p21 in 
S6/flox (CRE+) and ΔS6/flox (CRE-) livers, before (T-72) and after (T-1) the induction of S6 
deletion by pIpC injection. (C) Expression levels of the 34S rRNA precursor in S6/flox and 
ΔS6/flox liver before surgery (T-1) and at the beginning of surgery (T0). 
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Establishment of an in vitro model for studying how defects in 
ribosome biogenesis affect the cell cycle: results 
 
The other aim of this part of the project was to establish an in vitro system that could 
mimic the disruption of ribosome biogenesis and the S-phase block observed in the 
ΔS6/flox mice. The establishment of such a system was prompted both by: (1) the 
inherent difficulty to dissect molecular pathways in vivo using a mouse model; and (2) 
the need for a model to test if the phenotype observed in vivo was cell autonomous. In 
order to establish such a system, I tested different experimental procedures to obtain 
S6-deficient cells in vitro and examine whether these systems reproduced the in vivo 
model. After successfully establishing an in vitro system, I characterized the 
mechanisms linking the loss of S6 to the block in S phase entry.  
 
o Use of primary hepatocyte cultures as models for the ΔS6/flox 
proliferation phenotype 
 
I first tested experimental procedures which relied on the use of cells derived from the 
S6/flox mice, since I thought they would be more likely to mimic the mouse model. I 
isolated mouse embryo fibroblasts (MEFs) from S6/flox animals, which harbored the 
Mx-Cre recombinase transgene (Cre+), and stimulated Cre expression by adding either 
polyinosinic-polycytidilic acid (pIpC), an inducer of IFN-α, or IFN-α itself to the culture 
medium. Unfortunately, using this approach I was unable to induce disruption of the S6 
gene. 
 
Therefore, I tested procedures in which I could induce the deletion of the gene in vivo 
and subsequently isolate and culture the S6 knockout cells. The injection of pIpC into 
S6/flox Cre+ mice causes full deletion of the gene in liver but not in other tissues 
(Volarevic, Stewart et al. 2000). Following this observation, I cultured hepatocytes 
isolated from newborn mice. Livers of newborn mice are not fully structured, and 
hepatocytes can be isolated through a simple collagenase digestion. Furthermore, in 
contrast to adult hepatocytes, hepatocytes from newborns have a higher proliferating 
potential in vitro (Hamamoto, Kamihira et al. 1999), undoubtedly an advantage when 
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studying cell cycle progression. This procedure required, however, the induction of the 
S6 deletion in newborn mice. Setting aside the difficulty of injecting mice of such a 
small size, both pIpC and IFN-α induced only a partial deletion of S6 in the livers of 
newborns.  
 
I next devised a procedure to isolate hepatocytes from adult mice, knowing that a pIpC 
injection could induce full deletion of S6 in liver. I successfully isolated and cultured 
hepatocytes from both ΔS6/flox and S6/flox. Hepatocyte proliferation in response to 
insulin, in conjunction with either epidermal growth factor (EGF) or hepatocyte growth 
factor (HGF), was tested by measuring the incorporation of 3H-labelled thymidine. Both 
treatments induced an increase in DNA synthesis in both ΔS6/flox and S6/flox 
hepatocytes. Consistent with the results in vivo, less thymidine was incorporated in 
ΔS6/flox hepatocytes (Fig.17), indicative of a defect in S-phase entry.  
 
  
o SiRNA-mediated knockdown of S6 in A549 cells  
Primary adult Hepatocytes provided a useful tool to test if the effects caused by 
deletion of the S6 gene were cell autonomous, but they also presented some limitations 
because of their limited lifespan and proliferation rate. Therefore, I turned towards the 
use of siRNA as a method to knockdown expression of the S6 ribosomal protein. 
SiRNA-mediated knockdown involves the use of small RNA oligomers to trigger the 
Fig.17 Levels of thymidine 
incorporation in S6/flox and 
ΔS6/flox primary adult 
hepatocytes. The cells were 
seeded for 4 hours after 
perfusion from the liver and 
starved for 18 hours, after which 
3H-thymidine was added. The 
cells were collected 72 hours 
after thymidine addition. 
Hepatocyte proliferation was 
induced by addition of Insulin (2 
mg/ml) and either EGF (20 
g/ml) or HGF (10 g/ml) after 
the period of starvation 
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degradation of a target mRNA (Elbashir, Lendeckel et al. 2001). I transfected A549 
cells with two different siRNAs directed against the human S6 ribosomal protein and 
compared them for the expression of S6 in cells which were either untreated, or treated 
with a non-silencing (NS) siRNA control, to correct for any non-specific effects caused 
by the siRNA treatment itself. Both of the siRNAs for S6, but not the NS siRNA, caused 
depletion of S6 mRNA at 24 hours after transfection (Fig.18A): these changes were 
also reflected at the protein level (Fig.18B). For all the subsequent experiments I used 
S6 siRNA (#2), which proved to be more efficient. Immunohistochemical analysis of S6 
siRNA-treated cells using an antibody against S6 revealed a decrease in the staining of 
S6 in the nucleolus but not in the cytoplasm, where S6 is associated with ribosomes 
(Fig.18C).  
 
o Knockdown of S6 by siRNA causes a reduction in the number of 40S 
ribosomal subunits and accumulation of a 34S precursor of 18S 
rRNA 
 
With the possibility of lowering S6 levels in vitro, I testedthe extent to which this system 
mimicked the phenotype  of the ΔS6/flox mouse. In vivo, deletion of S6 affects the 
ability of hepatocytes to synthesize new 40S ribosomal subunits (Volarevic, Stewart et 
Fig.18 (A) RNA levels of ribosomal protein S6 24 hours after transfection with (i) nothing; (ii) 
15nM S6 siRNA (#1); (iii) 15nM S6 siRNA (#2); (iv) 15nM non-silencing siRNA. (B) S6 protein 
levels using the same treatments as above. (C) Immunohistochemistry using S6 antibody: 
(top) cell treated for 24 hours with 15nM non-silencing siRNA; (bottom) cell treated for 24 
hours with 15nM S6 siRNA(#2) 
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al. 2000) due to a defect in rRNA processing that leads to the accumulation of a 34S 
precursor of the 18S rRNA. In contrast, no effect is observed on the production of 28S 
rRNA, which is associated with the 60S large ribosomal subunit (Volarevic, Stewart et 
al. 2000). To determine whether the knockdown of S6 in vitro caused a similar effect, I 
used polysome profiles of cytoplasmic extracts from S6 siRNA-treated cells. Like in 
ΔS6/flox animals, the depletion S6, as compared to NS siRNA-treated cells, caused a 
decrease in the numbers of both 40S subunits and polysomes, indicative of a possible 
effect on translation rates (Fig.19A). As a complement to this experiment, in order to 
determine the effects of S6 depletion on the production of 18S rRNA, I also used RNA 
gradients to measure mature rRNA levels. If we consider the ratio between 18S and 
28S rRNA in cells treated with NS siRNAs to be 1, the value was clearly altered in cells 
treated with the S6 siRNA, due to a drop in production of 40S ribosomal subunits 
(Fig.19B). The defect in production of 18S was due to a failure in processing the 34S 
rRNA precursor as shown by northern blot using a specific probe for the 34S RNA 
precursor. The 34S RNA was observed in cells treated with the S6 siRNA but not in 
cells treated with NS siRNA. 
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o Knockdown of S6 causes a cell cycle block and induces a p21/p53 
response 
 
After establishing that in vitro depletion of S6 causes a defect in ribosome biogenesis, I 
went on to test whether, as seen in ΔS6/flox, this defect could lead to a cell cycle block. 
To answer this question I perfomed a FACS analysis of cells using BrdU pulse-labelling. 
The cells were treated with BrdU for 10 minutes and then collected. BrdU is a modified 
nucleotide that integrates only in the DNA of cells which are undergoing DNA synthesis. 
Fig.19 (A) Polysome profiles of cells treated with either non-silencing (NS) siRNA or 15nM S6 
siRNA (#2) for 24 hours. (B) rRNA profile showing 18S and 28S rRNA of cells treated with 
either non-silencing (NS) siRNA or 15nM S6 siRNA (#2) for 24 hours. The red area represents 
the difference in height between the two rRNA peaks. (C) Northern blot against 34S rRNA 
precursor. In vitro experiments with siRNA and in vivo experiments with S6/flox mice after 
hepatectomy were compared: the diagram shows the location of the designed probe on the 
45S rRNA precursor. Two different probes were used to detect the human and the mouse 
34S. Lane 1 NS siRNA 15nM, Lane 2 S6 siRNA (#2) 15nM, Lane 3 S6/flox liver 30 hours post-
hepatectomy, Lane 4 ΔS6/flox liver 30 hours post-hepatectomy 
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FACS analysis of the cells fixed and incubated with a fluorescent anti-BrdU antibody 
allows the quantification of BrdU-positive cells, providing a measure of the percentage 
of cells undergoing S phase. The cells were also treated with propidium iodide, to stain 
their DNA and allow the measurement of their distribution in the G1 and G2 phases of 
the cell cycle. In a first experiment, the cells were treated with either NS or S6 siRNA, 
and collected at 24 and 48 hours after treatment. At both timepoints, S6-treated cells 
displayed a decrease in S-phase and an increase in G1-phase population when 
compared to NS siRNA-treated cells (Fig.20). In agreement with these results, a 
biochemical characterization showed that the levels of Rbl1, a marker of cell 
proliferation, were lower in S6 siRNA-treated cells (Fig.21). The correlation between 
these data and the findings of the in vivo mouse model prompted us to test whether 
p21 and its upstream inducer, p53, were upregulated in cells treated with the S6 siRNA. 
Indeed, western blot analysis showed that both p21 and p53 were heavily induced in 
response to the S6 knockdown (Fig.21). 
o P21 and p53 can rescue the S6-induced cell cycle block in vitro 
 
To investigate whether p21 or p53 could be responsible for the block in S phase entry 
induced by downregulation of S6, I tested whether the simultaneous depletion of either 
of them could rescue the defect in cell proliferation caused by the lack of S6. For this 
purpose, A549 cells were treated with S6 siRNA in combination with either a p21 or 
p53 siRNA. At 24 and 48 hours after transfection, we measured the number of cells 
entering S phase through BrdU incorporation and FACS analysis. As a control, I used 
cells treated with S6 siRNA in combination with NS siRNA to compensate for any 
unspecific effect caused by the total amount of siRNA present (30nM total). 
Interestingly, depletion of p21 in S6 knockdown cells resulted in a partial rescue of S-
phase entry. The effect, however, was even more pronounced in cells where p53 was 
downregulated, as shown by the number of cells in S phase, which nearly corresponds 
to the one of NS siRNA-treated cells (Fig.22A and B). I performed a biochemical 
analysis at 24 hours in order to determine, the efficacy of the depletion of the targeted 
proteins and to analyze the expression of p107. In Cells treated with p53 siRNA p21 
protein levels were diminished, showing that, in this system, the upregulation of p21 is 
solely dependant on p53. With regards to proliferation, Rbl1 levels paralleled the results 
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obtained with the BrdU incorporation, showing rescue of the S6 knowckdown 
phenotype in cells treated with p53 siRNA (Fig.22C). 
 
 
Fig.20 Cell cycle analysis of cells treated with either 15nM non-silencing (NS) siRNA or 15nM 
S6 siRNA. (A) Profile showing ploidy (x-axis) over number of cells (y-axis) at 24 or 48 hours 
after treatment. Values represent the percentage of cells in either G1 or G2 phase and are 
representative of one experiment. Replicate experiments gave similar results. (B) Percentage 
of BrdU-positive cells normalized to the NS control for each timepoint: values derive from 
average of three independent replicates 
Fig.21 Biochemical 
analysis of cells 
treated with either 
15nM non-silencing 
(NS) siRNA or 15nM 
S6 siRNA for 24 
hours. The levels of 
S6, Rbl1, p21 and 
p53 are shown 
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Having established that depletion of both p21 and p53 can revert the block in S phase 
elicited by S6 downregulation, I assessed whether the same treatment also rescued 
cell division. For this purpose, I counted the number of cells at 24, 48 and 72 hours 
after transfection with different combinations of siRNAs. Surprisingly, in conditions that 
rescued S-phase entry the number of cells was much lower than the NS treated cells, 
(Fig.23). Frthermore at 48 hours after transfection, cells treated with S6 and p53 
Fig.22 Cell cycle analysis of cells treated with either: (i) 30nM non-silencing (NS) siRNA; (ii) 
15nM S6 + 15nM NS siRNA; (iii) 15nM S6 + 15nM p21 siRNA; (iv) 15nM S6 + 15nM p53 
siRNA. (A) Profile showing ploidy (x-axis) over number of cells (y-axis) at 24 or 48 hours after 
treatment. Values represent the percentage of cells in either G1 or G2 phase and are 
representative of one experiment. Replicate experiments gave similar results. (B) Percentage 
of BrdU-positive cells normalized to the NS control for each timepoint: values derived from the 
average of three independent replicates. (C) Western blot showing levels of S6, p53, p21 and 
Rbl1 24 hours after siRNA transfection 
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siRNAs showed an increase in G2 phase of about 6-10% as compared to NS siRNA-
treated cells. Altogether evidence is provided showing that the effect of S6 depletion on 
the cell cycle is mediated by the activation of a p53-dependent pathway and, in part, 
upregulation of p21. However, although downregulation of p53 in S6-depleted cells 
rescues S-phase entry, it is not sufficient to rescue cell division. 
 
 
o Knockout of p21 rescues S6-induced cell cycle block in ΔS6/flox 
livers 
 
In view of the results obtained in vitro, we were interested to see if the hepatocyte 
proliferation of ΔS6/flox animals could be rescued by the downregulation of p21. For 
this purpose, we generated S6/flox mice positive for the Mx-Cre transgene and carrying 
a homozygous p21 gene deletion. In so doing, upon induction of Cre expression by 
injection of pIpC, we obtained ΔS6/flox   p21-/- mice. We performed partial 
hepatectomy on these mice and assessed the capacity of the liver cells to enter the first 
round of S phase. For this purpose, at we injected the mice intraperitoneally with BrdU 
following hepatectomy. Livers were then extracted at 40 hours after hepatectomy and 
conditioned for histoimmunochemistry with anti-BrdU antibodies. Interestingly, we found 
BrdU positive hepatocytes in the liver of the ΔS6/flox p21-/- mouse, indicating the 
presence, albeit limited, of proliferation. (Fig.24). These data suggest that, also in vivo, 
Fig.23 Histogram showing 
number of A549 cells 
present in a 10cm culture 
dish after treatment with 
either: (i) 30nM non-
silencing (NS) siRNA; (ii) 
15nM S6 + 15nM NS 
siRNA; (iii) 15nM S6 + 
15nM p21 siRNA; (iv) 
15nM S6 + 15nM p53 
siRNA. Cells were 
collected at 24, 48 or 72 
hours after transfection. 
The Values represent the 
average of three 
independent replicates 
Page - 42  
 
 
p21 is a crucial player in the cell cycle checkpoint elicited by inhibition of ribosome 
biogenesis. 
 
 
o The ribosome biogenesis checkpoint is triggered by other ribosomal 
proteins 
 
The data presented so far concern the effects on cell cycle progression of the depletion 
of S6, one of about 80 ribosomal proteins. To test whether the abrogation of other 
ribosomal proteins would result a cell cycle block, I performed experiments with siRNA 
directed against L7a and S23, two ribosomal proteins of the large and small ribosomal 
subunit respectively. The depletion of either of these two proteins caused an increase 
in the expression of p21 mRNA, as shown by northern blot analysis (Fig.25).  
 
Fig.24 Immunohistochemical analysis of BrdU-positive cells in the livers of: (i) 
S6/flox; (ii) S6/flox; and (iii) ΔS6/flox p21-/- 40 hours after partial hepatectomy. 
Proliferating cells are shown in red 
Fig.25 (A) mRNA levels of S23 and L7a after 24 
hours' treatment of A549 cells with either: (i) 15nM 
non-silencing siRNA; or (ii) 15nM siRNA against S23 
or L7a. (B) Levels of p21 mRNA in response to the 
same siRNA treatments 
Page - 43  
 
 
Discussion 
 
S6 deletion in mouse livers inhibits the transcription of genes 
involved in S-phase progression 
 
The microarray analysis of  S6/flox versus ΔS6/flox livers following hepatectomy shows 
the differential expression of a number of genes involved in cell cycle progression. 
Therefore, the lack of cyclin E expression observed by (Volarevic, Stewart et al. 2000) 
is not the sole event responsible for the absence of cell proliferation in ΔS6/flox mice. 
Instead, the expression of a whole plethora of factors involved in cell cycle control and 
DNA metabolism fails to be induced in ΔS6/flox livers. The number of genes 
differentially expressed increases proportionally with time, in particular between 20 and 
30 hours after hepatectomy. Since the 30-hours timepoint corresponds to the mid-to-
late G1 phase, as shown by the rise in Rbl1 mRNA, the shift in the number of 
differentially expressed genes is most probably due to the upregulation of the cell cycle 
machinery in S6/flox but not in ΔS6/flox mice. It is not possible to rule out, however, a 
defect in other cellular processes that do not rely on transcriptional regulation. In 
ΔS6/flox livers, the correlation between the lack of expression cell cycle inducer genes, 
such as the cyclins, and the induction of cell cycle inhibitors, like p21, hints at the 
existence of a checkpoint mechanism that acts coordinately in response to S6 deletion 
and to the inhibition of ribosome biogenesis.  
 
S6 inhibits E2F1-mediated transcription of genes involved in cell 
cycle progression 
 
Transcription of most of the genes that fail to be upregulated in ΔS6/flox has been 
reported to be dependent, at least partly, on E2F transcription factors. During the G1 to 
S transition, there is an increase in E2F1-dependent transcription, as shown in S6/flox 
livers at 40 hours. In ΔS6/flox livers, a defect in E2F1 activity is suggested by the lack 
of E2F1 mRNA upregulation, as shown both by microarray and northern blot analysis 
and by the absence of induction of direct transcriptional targets of E2F1, such as Rbl1.  
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Hepatocytes in a resting liver are quiescent and confined in the G0 phase of the cell 
cycle. Partial hepatectomy triggers a proliferative response which requires the gradual 
exit from G0, an event largely dependent on the phosphorylation of the pocket protein 
Rbl2 (Mayol, Garriga et al. 1995; Garriga, Limon et al. 1998). Our experiments show 
that, after partial hepatectomy, Rbl2 remains hypophosphorylated in ΔS6/flox livers and 
maintains a DNA-bound conformation, as shown by electromobility shift assays. The 
presence of Rbl2/E2F4 complexes on the promoters of E2F-responsive genes would 
sterically hinder the binding of E2F1 and, therefore, its ability to activate transcription 
(Grana, Garriga et al. 1998). Since E2F1 activates its own transcription in a feed-
forward mechanism, its expression will also be inhibited in these conditions.  
 
Cyclin E is not sufficient to rescue the cell cycle arrest caused by S6 
depletion 
 
Together with Cdk4 and Cdk6, Cdk2 participates in the phosphorylation of pocket 
proteins such as Rbl2 and the consequent relief of their inhibition. Since Cdk(4,6) 
activity is not influenced by the deletion of S6 (Volarevic, Stewart et al. 2000), we can 
argue that a lack of Cdk2 activity could cause the defect observed in cell cycle 
progression. This hypothesis has been confirmed by a series of experiments performed 
in our lab (S. Fumagalli, unpublished results), which aimed at rescuing the S-phase 
entry in these livers by overexpressing cyclin E. The rationale behind this approach is 
that ectopic expression of cyclin E can induce S-phase entry even without the 
activation of the E2F pathway (Lukas, Herzinger et al. 1997). Two different approaches 
were used. The first relied on the use of adenovirus expressing human cyclin E, while 
in the other approach the ΔS6/flox mice were crossed with mice containing a knock-in 
of the cyclin E cDNA on the cyclin D locus (Geng, Whoriskey et al. 1999). Both systems 
successfully induced cyclin E expression. However, surprisingly the block in S-phase 
entry is maintained in these conditions. Co-immunoprecipitation experiments showed 
the presence of cyclin E/Cdk2 complexes, but a lack of any associated Cdk2 activity. 
 
Upregulation of p21 inhibits S-phase entry in ΔS6/flox livers 
 
Page - 45  
 
 
Given the failure of cyclin E to rescue the phenotype, it is plausible that a lack of Cdk2 
activity, rather than the absence of cyclin/Cdk2 complexes, would cause the inhibition 
of cell cycle progression. This was supported by the later observation that levels of p21, 
a Cdk2 inhibitor, are higher in ΔS6/flox livers, as shown by data from both microarray 
analysis and western blotting. It must be said that we initially excluded a role for p21 in 
this inhibition, since previous reports (Volarevic, Stewart et al. 2000) showed a normal 
regulation of p21 protein levels in ΔS6/flox livers. The reason for this discrepancy lies in 
the timing of p21 expression. Volarevic et al. measured the levels of p21 at 0 and 40 
hours after hepatectomy and noticed the same extent of upregulation of the protein in 
both S6/flox and ΔS6/flox livers. This data confirms this observation but provides 
evidence that at timepoints preceding 40 hours the levels of p21 are markedly higher in 
ΔS6/flox livers.  
 
To determine whether p21 is involved in the block of S-phase entry ΔS6/flox mice were 
crossed with p21 knockout mice. When subject to hepatectomy, ΔS6/flox p21-/- livers 
show proliferating cells 40 hours after surgery, albeit to a lower extent than the control 
S6/flox livers. p21 therefore participates in the G1 block caused by the deletion of S6. 
Although the experiments have yet to be performed, we expect that Cdk2 activity will 
be recovered in the absence of p21. The reason why the ΔS6/flox p21-/- liver did not 
provide a full rescue could be attributed to the participation of other proteins in this 
response or by the different timing of S-phase entry in this genetic background. 
Experiments with different kinetics should provide a clearer answer to this issue. 
 
Defects in ribosome biogenesis are sensed early 
 
p21 mRNA is already upregulated in resting ΔS6/flox livers. Similarly, in the same 
situation the accumulation of the 34S precursor of the 18S rRNA is detected. Both of 
these observations reflect that S6 depletion causes a defect in ribosome biogenesis 
and subsequent activation of the checkpoint, even in the absence of proliferative stimuli. 
In this respect, it has to be emphasized that ribosome biogenesis is a continuous event 
which takes place also in resting hepatocytes, and its perturbation, upon depletion of 
S6, would therefore be sensed in the period preceding partial hepatectomy. If this is the 
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case, however, why would there be an induction of cyclin D/Cdk4 activity in ΔS6/flox 
livers after hepatectomy? (Volarevic, Stewart et al. 2000). It is possible that the role of 
cyclin D/Cdk4 activity in this context is dissociated from its function in cell cycle 
progression, and that it participates instead in other cellular processes, such as cell 
growth or dedifferentiation. This hypothesis is supported by the fact that cyclin D is 
dispensable in the liver regenerative response (Geng, Whoriskey et al. 1999). 
Alternatively, induction of cyclin D and activation of Cdk4 could result from cellular 
events which are not sensitive to alterations in ribosome biogenesis.  
 
Deletion of S6 by siRNA in A549 cells mimics the ΔS6/flox liver 
phenotype 
 
In order to build an in vitro system that mimics the ΔS6/flox mouse model, siRNA 
technology was used to deplete S6 in the A549 cell line. The siRNA was effective in the 
downregulation of both S6 mRNA and protein, even at 24 hours after transfection. 
Interestingly, the immmunohistochemical analysis reveals that the siRNA treatment 
mainly affects the nucleolar pool of S6, whereas S6 cytoplasmic staining does not 
seem to decrease significantly. This observation probably reflects the depletion of 
nascent S6 proteins, which are synthesized in the cytoplasm and then transported in 
the nucleolus for 40S assembly. Instead, the cytoplasmic staining is due to the S6 
protein associated with ribosomes, which are notoriously stable, although analysis of 
the polysome profiles would suggest that the content of the 40S ribosomal subunit 
decreases upon S6 depletion. Depletion of S6 by siRNA in A549 cells causes all the 
phenotypical characteristics associated with the deletion of the S6 gene in vivo, such 
as the impaired synthesis of the 40S ribosomal subunit and the concomitant 
accumulation of a 34S precursor of the 18S rRNA (Volarevic, Stewart et al. 2000). 
Furthermore, when compared to cells treated with non-silencing siRNA, cells where S6 
was downregulated accumulated in G1, due to a defect in progression to S phase.   
 
Deletion of S6 causes a p53-dependent cell cycle arrest 
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Similarly to what is observed in ΔS6/flox livers, downregulation of S6 by siRNA in A549 
cells triggers the upregulation of p21. In the context of a cell cycle checkpoint, p21 
upregulation is often associated with the transcriptional activity of p53 like, for example, 
in the response elicited by DNA damage (el-Deiry, Tokino et al. 1993). Although 
upregulation of p21 was observed in vivo, we lack direct evidence of an increase in p53 
activity in that system. However, several p53 targets, such as Bax and Gadd45γ, are 
upregulated in ΔS6/flox livers, suggesting that p53 could play a role in the activation of 
the checkpoint. Using the in vitro system, I was able to take the model one step further 
and show that the p53 protein levels increase in response to the depletion of S6 by 
siRNA. Furthermore, I show that p21 induction is solely dependent on p53, since the 
depletion of p53 ablates the induction of p21. I also established that p21 and p53 are 
both involved in the cell cycle block induced by the lack of S6. In fact, if downregulation 
of p21 causes a partial rescue of S-phase entry, ablation of p53 fully rescues the ability 
of S6-deficient cells to enter S phase, to levels barely distinguishable from the ones of 
control cells. It is likely, as seen in vivo, that the upregulation of p53 in S6-deficient cells 
causes the induction of a number of genes, besides p21, that cooperate to cause a cell 
cycle arrest, explaining why the suppression of p21 alone is not sufficient to fully 
restore S-phase entry.  
 
An important conclusion from the rescue experiments is that S phase can proceed 
even while the defect in ribosome biogenesis is still present. This supposes that the 
pool of ribosomes existing before S6 depletion provides sufficient translation capacity 
to drive cells through S phase. What is the reason, therefore, behind the upregulation 
of ribosome biogenesis during cell cycle progression? And why would a checkpoint 
mechanism exist at this stage? One possibility is that the upregulation of ribosome 
biogenesis in proliferating cells is mostly required to provide an adequate pool of 
ribosomes for the daughter cells, and that activation of the checkpoint would occur in 
circumstances where this task could not be met.  
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Is the upregulation of p53 only dependent on S6 and 40S disruption? 
 
Using siRNA against two other ribosomal proteins, S23 and L7a, of the small and the 
large ribosomal subunit, respectively, I was able to detect the upregulation of p21 
mRNA, suggesting that a defect of at least two other ribosomal proteins triggers a 
response similar to the one elicited by S6 downregulation. Furthermore, other groups 
have reported a relationship between defects in ribosome biogenesis, p53 upregulation 
and cell cycle inhibition. The manuscript from (Pestov, Strezoska et al. 2001), for 
example, describes studies on the protein Bop1 which they identified in a genetic 
screen for cDNAs that caused a reversible perturbation of cell cycle progression. Bop1 
was shown to be involved in the processing of the precursor of the 28S rRNA, which 
assembles in the 60S large ribosomal subunit. Functional inactivation of Bop1 leads to 
the failure of 60S subunit synthesis, caused by defects in the maturation of the 28S 
rRNA, without affecting the production of 40S subunits. Cells defective in Bop1 function 
are blocked in G1 and show upregulation of p53. In the same background, inhibition of 
p53 by the E6 oncoprotein restores normal S-phase progression. Together with our 
data, these results show that defects in the biosynthesis of either the 40S or 60S 
ribosomal subunits block cell cycle progression through the induction of p53.  
 
Upregulation of p53 in response to defects in ribosome biogenesis 
 
The mechanisms that control upregulation of p53 in response to defects in ribosome 
biogenesis are still unclear, but two potential mechanisms have recently been 
proposed.The first one, described in (Sugimoto, Kuo et al. 2003), proposes a role for 
the p19Arf protein in the upregulation of p53. P19Arf mediates the stabilization of p53 by 
protecting it from Mdm2-mediated proteolisis (Tao and Levine 1999; Weber, Taylor et al. 
1999; Zhang and Xiong 1999). The p19Arf mRNA is transcribed from an alternate 
reading frame of the p16ink4a locus and its expression is upregulated in response to 
oncogenic and hyperproliferative signals (Sherr 1998). Upregualtion of p19Arf induces a 
cell cycle block in both G1 and G2, which is mediated through p53 stabilization (Quelle, 
Zindy et al. 1995). Sugimoto et al. show that the overexpression of p19Arf inhibits 
ribosome biogenesis in a p53-independent manner, proposing a novel role for this 
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protein. This effect is elicited by p19Arf-mediated degradation of B23, a protein involved 
in the maturation of 28S rRNA (Hadjiolova, Normann et al. 1994). The authors propose 
that the upregulation of p19Arf by oncogenic signals could trigger a p53-mediated cell 
cycle block and at the same time stop ribosome biogenesis through the disruption of 
60S formation. Although we cannot exclude it, such a mechanism would be unlikely to 
work in our experimental system: in fact, as already mentioned, p19Arf expression is 
mainly induced by oncogenic stimuli, like overexpression of E2F1, which seem instead 
to be absent S6-depleted cells both in vitro and in vivo.  Furthermore, Sugimoto et al. 
argue that defects in ribosome biogenesis parallel the inhibition of cell cycle 
progression, while our data suggest that it is indeed the defect in ribosome biogenesis 
that causes the cell cycle block. Last but not least, the production of 60S ribosomal 
subunits proceeds normally in S6-depleted cells. In conclusion, although appealing, the 
described model does not fit with the current data, but it could yet represent another 
coordination mechanism between the cell cycle and ribosome biogenesis. 
 
Another model was proposed by three different groups, who all identified a subset of 
ribosomal proteins that directly promotes p53 stabilization. In particular, it was shown 
that L5, L11, and L23, all proteins from the 60S ribosomal subunit, were able to bind 
and inhibit the Mdm2 ubiquitin ligase, promoting the stabilization of p53 (Lohrum, 
Ludwig et al. 2003; Bhat, Itahana et al. 2004; Dai and Lu 2004; Jin, Itahana et al. 2004). 
The overexpression of L11, for example, led to the upregulation of p53 protein levels 
(Bhat, Itahana et al. 2004). According to the model of Bhat et al., non-ribosome-bound 
L11 interacts with Mdm2 and triggers the upregulation of p53 when in excess. Such a 
situation would be mimicked by the inhibition of rRNA transcription with low doses of 
actinomycin D, a treatment that is in fact shown by Bhat et al. to trigger L11-mediated 
upregulation of p53. Similarly, the authors argue, any physiological defect in 60S 
synthesis would lead to the accumulation of free L11, a consequent increase in p53 
levels and, ultimately, to cell cycle block. Indeed, depletion of L11 was sufficient to 
eliminate the p53 upregulation caused by actinomycin D treatment. L5 and L23 show a 
similar behavior, although their depletion does not fully abolish the induction of p53 (Dai 
and Lu 2004; Jin, Itahana et al. 2004). All three of these proteins are dispensable for 
ribosome biogenesis and translation as shown by knockdown experiments using siRNA 
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(Bhat, Itahana et al. 2004; Dai and Lu 2004; Jin, Itahana et al. 2004). It is therefore 
likely that the proposed role for these proteins constitutes an extra ribosomal function. 
We cannot exclude the possibility that depletion of S6 causes an L11-, L5-, or L23-
mediated induction of p53. If that were the case, however, our data would not agree 
with the fact that disruption of 60S synthesis is a prerequisite for this response. 
Interestingly, on top of the effect caused by the overexpression of L23, its 
downregulation also causes a weak induction of p53 and cell cycle arrest (Jin, Itahana 
et al. 2004), a situation reminiscent of the phenotype caused by S6 depletion. It is 
tempting to speculate that different mechanisms might sense either the lack or the 
excess of ribosomal proteins with respect to the amount of rRNA present. The effects of 
S6 overexpression could maybe provide some insight for such a mechanism. 
 
Downregulation of p53 rescues S phase but not cell number 
 
The experiments reorted show that although the downregulation of p53 can nearly fully 
rescue the S-phase arrest caused by S6 depletion in A549 cells, it does not result in an 
increase in cell number. In fact, the number of cells treated with a combination of p53 
and S6 siRNAs remained roughly the same as the number of cells treated with the S6 
siRNA alone, throughout the experiment. Further studies will be required to understand 
the mechanisms that participate in this block. We can exclude, however, the 
involvement of an apoptotic response, since no sub-G1 peak was detected by the 
FACS analysis. On the contrary, at 48 hours after transfection, the cells treated 
simultaneously with the S6 and p53 siRNAs showed a small but significant increase in 
the G2 population, as compared to the non-silencing controls. It is tempting to 
speculate that a second p53-independent checkpoint exists, that detects defects of 
ribosome biogenesis in the G2-M phase of the cell cycle. In the response to DNA 
damage, a mechanism operates, mediated by the Chk1 and Chk2 kinases, which 
inhibit Cdk1 activity (and therefore progression through mitosis) through the 
degradation of Cdc25c phosphatase. Interestingly, two publications from the same 
laboratory (Bhat, Itahana et al. 2004; Jin, Itahana et al. 2004) show FACS analysis 
profiles of cells treated with siRNA against L11. Although the authors claim that 
depletion of L11 does not induce a cell cycle block, they fail to comment on the 
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increase in G2 phase observed upon this treatment. Unfortunately, those papers do not 
provide data on cell numbers. This, and our observations, might be linked to the same 
mechanism.  
 
Ribosome biogenesis as a therapeutic target  
 
A recent publication by Rubi et al. (Rubbi and Milner 2003) provides an interesting 
report on the importance of the nucleolus and its function in ribosome biogenesis in 
cellular homeostasis. They first show that, surprisingly, the p53 response ttriggered by 
UV irradiation derives from the disruption of nucleolar integrity rather than from damage 
to the DNA itself, showing therefore that the nucleolus is under tight repair process 
monitoring. Furthermore, a good number of commercial drugs used for cancer 
treatment due to their pro-apoptotic properties are inhibitors of ribosome biogenesis. 
The author cites examples such as actinomycin D and cysplatin, suggesting that the 
disruption of ribosome biogenesis can therefore be lethal even for cancer cells. Indeed, 
our own studies go in the same direction. The A549 cells used in our studies are 
derived from a small cell lung carcinoma and proliferate fast in culture. Yet treatment 
with S6 siRNA and consequent disruption of ribosome biogenesis is sufficient to trigger 
a block in S phase through upregulation of p53. One problem, however, may arise from 
the fact that p53 is often mutated or repressed in malignant cancers. Nevertheless, our 
results suggest that downregulation of p53 allows progression through S phase but 
prevents cell division in cells where ribosome biogenesis is disrupted, reinforcing the 
idea that the process of ribosome biogenesis may be an ideal therapeutic target 
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Materials and methods 
Mouse genotyping 
Mice homozygous for RpS6-floxed genes were screened for the presence of the Mx-
Cre transgene by PCR using a modification of the protocol from (Liu, Grinberg et al. 
1998). The following nucleotides were used:  
 
Cre 5’ (5’-AATGCTTCTGTCCGTTTGCCGGT-3’) 
Cre 3’ (5’-CCAGGCTAAGTGCCTTCTCTACA-3’).  
 
About 25mm of each mouse tail was cut using a sterile razor blade. The piece of tail 
was then incubated in 600μl 50mM NaOH solution for 3-4 hours until completely 
disaggregated. The NaOH was neutralized using 50μl 1M Tris-HCl pH 8.0. The 
samples were centrifuged for 6 minutes at 14,000 rpm on a bench centrifuge to pellet 
the debris. The supernatant was transferred into a fresh Eppendorf tube and then used 
for the PCR reaction. In order to increase the specificity of the analysis, a two-step PCR 
reaction was performed. 
 
1µl DNA template  
4µl dNTP (20 mM) Qiagen 272050  
2.5µl PCR buffer (1.5mM MgCl2) Qiagen 1005476 
0.3µl Taq polymerase Qiagen 1005476 
0.25µl primer 5’  Cre 5’ 
0.25µl primer 3’  Cre 3’ 
16.7µl H20  
 
The following PCR reaction protocol was used: 
 
95°C  5 min 
95°C 1 min * 
68°C 1 min * 
72°C 1 min * 
95°C 10 min 
 
* Repeated for 15 cycles.    
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At the end of the reaction, 1µl of each PCR reaction was used as a template for the 
second PCR reaction. The second PCR reaction was performed in exactly the same 
manner, but the cycles were repeated for 40 cycles rather than 15.  
The length of the amplified fragment is approximately 600 bp.  
 
Hepatectomy 
 
In all the experiments cited, the deletion of the gene in vivo was induced by a single 
intra-peritoneal injection of P(I)P(C) (P-1530). The pIpC solution was prepared by 
diluting the P(I)P(C) stock (5mg/ml) in PBS warmed at room temperature. 500µl 
solutions were then injected into each mouse using a BD Microlance 2006-04. The 
deletion was completed in the liver 72 hours post injection. 
 
All the animals used for the experiments were males between 3 months and 6 months 
of age. Both Mx-Cre– and Mx-Cre+ animals were injected with 250μg P(I)P(C) 72 hours 
prior to surgery. The mice were anesthetized with a mixture made of 12% Rompun (2% 
solution, Bayer 00730551) and 8% Narketan 10 (10mg/ml solution, Vetoquinol AG, 
Belp, Bern, Switzerland) in PBS. 100μl anaesthetic was injected I.P. for each 10g body 
weight. To compensate for the anaesthetic-induced lowering of body temperature, the 
mice were placed on a heating plate at 38°C for the entire surgical procedure. 
 
The mice were shaved and a skin incision was performed longitudinally from the plexus 
for 2cm. A small perpendicular incision was then made in the peritoneum just below the 
plexus. The incision was then extended by a small cut alongside the right side of the 
peritoneum until the thoracic cage was reached. The frontal and lateral lobes of the 
liver were then mechanically pushed out by digital massage. The lobes were ligated 
using a surgical silk thread around the extruded lobes with a double knot. The ligated 
lobes were excised using surgical scissors. The excised liver lobes were rinsed in PBS 
and immediately frozen in liquid nitrogen. The peritoneum was sutured using a surgical 
thread (Aesculap C0762113). The skin was closed using surgical clips (Becton 
Dickinson 427631). Animals were kept under a red heating lamp during the whole 
period of recovery from narcolepsy.  
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At given timepoints after partial hepatectomy the mice were sacrificed through cervical 
dislocation. The sutures were removed and the remaining liver lobes were washed in 
PBS to eliminate any residual blood and frozen immediately in liquid nitrogen.  
 
RNA extraction  
The RNA from the livers was extracted using the method of (Chomczynski P 1987). For 
microarray analysis, the RNA was further purified using the Rneasy Kits Purifications 
Protocol (Qiagen 74104). 
 
Northern hybridization  
Northern hybridization was performed using the method described in (Church and 
Gilbert 1984). The following oligonucleotide probes were used for the northern blot 
hybridization:  
 
34S rRNA (human) GGCGAGCGACCGGCAAGGCGGAGGTCGACCCACGC 
E2F1 GATACACTGGACGGTCCTGGAAGCGTCGTAACGTCTGGGACGTCTTCTACCAGTATC 
S6 GAGATGTTCAGCTTCATCTTGAAGCAGCTGAACGC 
 
The oligonucleotides were labeled at the 5’ terminus with γATP32, using the T4 PNK 
enzyme. For 20µl: 
 
18pmol oligonucleotide probe  
2µl 10x PNK buffer New England Biolabs 
5µl γATP32 20µCi/µl Amersham 
1µl T4 PNK enzyme New England Biolabs 
Water to 20µl  
 
All the oligonucleotide probes were hybridized at 56°C overnight in a rotating oven. The 
excess was washed out by three rapid washes in a 0.1% SDS/2xSSC solution followed 
by a 1 hour wash at 56°C in the same solution. The membranes were then exposed to 
a phosphoimager screen. P21 northern blots were performed using a cDNA probe and 
labeled using the RandomPrime labeling kit (Boehringher Ingelheim). 
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Microarray analysis 
Microarray hybridization was perfrormed following the protocols provided by Affymetrix 
(Affymetrix, Santa Clara, USA). The cRNA was hybridized to MGU-74A GeneChips™ 
(Affymetrix, Santa Clara, USA), washing and staining were performed in an Affymetrix 
Fluidics Station 450 and the samples were scanned in an Affymetrix GeneChip 3000 
scanner as per manufacturer’s instructions. Expression values were estimated using 
the robust multichip analysis algorithm (http://rmaexpress.bmbolstad.com). The 
expression analysis was performed using GeneSpring 6.2 (Silicon Genetics). Changes 
in gene expression were identified by requiring that a gene had a change in expression 
level at least 1.5-fold relative to the other genotype at one or more timepoints and pass 
a 1-way ANOVA (p<0.01) unless otherwise stated. 
 
Electromobility shift assay 
Electromobility gel shift assays (EMSA) used a modified protocol from (Garriga, Limon 
et al. 1998): 
 
A small piece of frozen liver was left to defrost in 1ml hypotonic solution (25mM Tris-
HCl pH7.5, 50mM KCl, 2mM MgCl2, 1mM EDTA, 5mM DTT, 5µg/µl aprotinin, 5µg/µl 
leupeptin, 1mM PMSF) for a few seconds. The sample was then homogenized using a 
Dounce tissue homogenizer (Wheaton 357542) with a loose pestle, in order to avoid 
disruption of the nuclei. Following incubation in ice for 5 minutes to allow cell swelling, 
the samples were centrifuged at 15,000g for 15 minutes at 4°C. After removal of the 
supernatant (cytoplasmic extract), the pellet was resuspended in 500µl hypotonic 
solution and centrifuged again in the same conditions in order to wash away further 
cytoplasmic contaminants. At the end of these washes the nuclei were still intact. To 
disrupt the nuclei, the pellet was resuspended in 200µl 5x EMSA extraction buffer 
(100mM hepes pH 7.4, 500mM KCl, 5mM MgCl2, 0.5mM NaF, 1mM DTT, 1mM PMSF, 
10µg/µl aprotinin, 10µg/µl leupeptin). The nuclei were left to swell for 30 minutes in ice 
followed by a 10-minute centrifugation at 15,000g at 4°C. The supernatant was 
recovered and stored in aliquots of 20µl at –80°C.  
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The bait DNA probe used was based on the E2F consensus sequence from the E2 
viral promoter: the mutated probe contains point mutations on the consensus sequence 
(Santa Cruz, sc-2507, sc-2508). For the formation of double-stranded DNA, equimolar 
amounts of the corresponding complementary strands were diluted in oligo-annealing 
buffer (20mM Tris HCl pH 7.5, 10mM MgCl2, 50mM NaCl), incubated at 95°C for 5 
minutes in a thermoblock and then left to cool gradually to RT. 25pmol of each dsDNA 
probe was then labelled using a T4 PNK enzyme (New England Biobabs). The mixture 
was incubated at 37°C for 1 hour. 
 
Labelling mixture: 
 
25pmol dsDNA 
γATP 32P (6,000Ci/μl) 7µl 
T4 PNK enzyme 2µl 
PNK buffer 2.5µl 
H20   To 25µl 
  
The reaction was performed by adding 10μg nuclear extracts to 80,000 cpm double-
stranded probe and 2μg salmon sperm DNA. The reaction was kept in ice for 10 
minutes for the binding to occur and then for 20 minutes at room temperature. The 
samples were run on a non-denaturating 4% PAGE for 2 hours at 280V. The gels were 
dried and exposed to film. Cold probe competition experiments and supershifting were 
performed in a similar manner, but the reaction was incubated for 1 hour on ice prior to 
the room temperature incubation. For cold competition, a 50-fold excess of cold wt or 
mismatched probe was used. For supershift, 1μl Rbl2 antibody was used.  
 
FACS analysis and BrdU labeling 
 
BrdU labeling was performed by adding 10μg/μl BrdU to the cell medium for 10 minutes 
before collection. The cells were then trypsinized and washed with PBS/BSA 1%. An 
anti-BrdU FITC-conjugated antibody (BD-347183) was used for BrdU detection. The 
washes and incubations were performed according to the manufacturer’s instructions. 
FACS analysis was performed using a FacsCalibur machine in association with the 
Modfit program. 
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RNA interference 
 
All the siRNAs were a kind gift from Francois Natt (Novartis, Basel, Switzerland). The 
sequences were developed using a proprietary algorithm developed by Novartis, which 
screens for target specificity.  
 
Name Target sequence 
S6 GTA AGA AAG CCC TTA AAT Att 
p21 TCA GCT GCT CGC TGT CCA Ctg 
p53 TTC CAC TCG GAT AAG ATG Ctg 
L7a TTG TTC TCC ACC AAG GTG Gtg 
S23 AAG GGT TGG CCT TTA GGG Ctg 
 
The siRNAs were transfected in A549 cells using oligofectamine (Invitrogen, Cat. No. 
12252-011) following the manufacturer’s instructions. 8μl oligofectamine was mixed 
with 12μl optimem. After 10 minutes' incubation, both solutions were mixed and the 
transfection mix was incubated for an additional 20 minutes. Just prior to transfection, 
target plates were washed once with 5ml optimem and the cells were covered with 1ml 
optimem and 200μl transfection mix. After 5 hours' incubation at 37°C and 5% CO2, the 
transfection mix was replaced with 5ml RPMI 1640 supplemented with 10% FCS. For 
10-cm plates the values were all multiplied by three (8μl oligofectamine were used for a 
6-cm dish).  
 
The oligofectamine/siRNA mixture was added to cells in optimem medium and 
incubated for 5 hours. The medium was subsequently replaced with RPMI 1640 
medium containing 10% FCS. The cells were collected at 24 or 48 hours after siRNA 
treatment. In most cases, 15nM (final) of each siRNA was added to the culture medium. 
A non-silencing (NS) siRNA (Quiagen, 1022076) was used as the negative control. In 
siRNA rescue experiments, the differences in total siRNA amounts were compensated 
for by the addition of the corresponding amount of NS siRNA. 
 
Polysome profiles and RNA sucrose gradients 
 
Polysome profile analysis was performed using protocols described in (Jefferies, 
Fumagalli et al. 1997). For RNA sucrose gradients, cells were extracted with solution D 
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(Chomczynski P 1987) and 0.2% SDS was added to the final extract. The samples 
were incubated for 1 minute at 60°C and spun in a microfuge for 5 minutes. The 
supernatant was layered on a 5.1-28.6% exponential sucrose gradient (100mM 
LiCl/10mM EDTA/10mM TrisCl pH7.4/SDS 0.2%) and ultracentrifuged at 60,000 rpm 
for 85 minutes at 20°C.  
 
Western blot 
Proteins were extracted using 50mM Tris HCl pH 7.4/5mM EDTA/250mM NaCl/50mM 
NaF/0.1% Triton X-100 + protease inhibitor tablets (Complete-Mini, Roche). For liver 
extracts, the samples were homogenized using a Dounce homogenizer. Protein 
samples were resolved by conventional SDS-PAGE and transferred onto PVDF 
membrane (Millipore), using a semidry transfer apparatus (LTF-Labortechnik).  
Blocking of the membrane was in Tris-Buffer Saline (TBS) supplemented with 0.02% 
Tween 20 and 5% milk. The following primary antibodies were used: mouse 
monoclonal anti-S6 (Novartis), rabbit polyclonal anti-L11 (a gift of Karen Vousden), 
rabbit polyclonal anti-p53 (Santa Cruz Biotechnology, FL-393), mouse monoclonal anti-
p21 (Pharmingen, cat. 556431) rabbit polyclonal anti-p107 (Santa Cruz Biotechnolgy, 
C-18), rabbit plyclonal anti-p130 (Santa Cruz Biotechnology, C20) 
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Bioinformatics 
Preface 
 
It is now well established that DNA microarray technology is an incredibly potent tool for 
biologists. It allows the simultaneous measurement of the expression levels of tens of 
thousands of transcripts, with full genome coverage arrays existing for many different 
organisms. The problem is, however, that while the result output from this technology is 
steadily increasing, the speed with which data can be analyzed is not. I became aware 
of this problem whilst analyzing my own microarray data, which consisted of a large 
number of conditions and replicates. In order to perform the analysis of my experiments, 
I automated several steps of this process to make it faster and more user-friendly. The 
software tools described in the following paragraphs were primarily developed for 
analysis of the microarray data generated in the course of my project. They found, 
however, a wider application amongst other users. Together with Dr. Edward Oakeley, 
at the FMI, I developed a set of software tools that could be used routinely for 
microarray analysis. Three programs were developed: ChangeMaker, which deals with 
the microarray analysis itself; MicroPlot which is used to visualize the data; and 
PromoterPlot which takes the next step in microarray analysis and deals with the 
identification of common patterns of transcription factors within promoters 
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ChangeMaker 
 
o Introduction 
The ChangeMaker program automates the comparison of microarray replicates.  
The motivation behind this program came from the analysis of livers after hepatectomy 
in response to the deletion of the ribosomal S6 protein. The experimental setup for this 
analysis consisted of the comparison of triplicate repeats of two genotypes over four 
timepoints, thus a total of 24 samples. Given the particular variability of expression data 
in animal models, requiring that genes must show the same behavior in all the 
replicates is often overly sensitive to outliers, with the effect that we might miss some 
potentially interesting candidate genes. It was therefore worth providing a degree of 
flexibility to the analysis, by analyzing genes that changed in most, but not necessarily 
all, of the replicates. I needed, therefore, to generate a set of data that would show the 
genes which changed significantly between each genotype, for each timepoint and in at 
least two of my three replicates. The software tools provided at the time by Affymetrix 
were limited and time-consuming for this type of analysis. This application was 
developed jointly with Dr. Edward Oakeley and was programmed in the VB.Net 
language. 
 
o Methods 
We devised a program that would make these comparisons automatically, without 
using the Affymetrix software. The input of the program is the Affymetrix CEL files 
which correspond to the 75th percentile of pixel brightness in each oligo spot from the 
raw scan generated by the Affymetrix GCS 3000 scanner. The CEL files are loaded 
into the program as groups of replicates with a user-defined name (Fig.1) 
 
 
 
 
 
Fig.1 Screen 
shot of 
ChangeMaker: 
the user loads 
the CEL files 
and places them 
into groups of 
replicates 
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The user is then prompted to choose which sets of replicates are to be compared. 
These can represent either comparisons of different timepoints or comparisons 
between different treatments or both (Fig.2).  
 
 
 
 
 
 
 
Following this step, the program performs the following tasks:  
 
1) The original CEL file and corresponding library files were very simple text files 
which could be loaded and parsed directly by our program. However, with the 
advent of the GeneChip Operating System (GCOS) from Affymetrix these files 
became binary so we had to make use of Affymetrix’s file-loader tool (file API) to 
handle newer files. Once the CEL files had been loaded, we had numerical 
values for the hybridization of each oligonucleotide on the array. 
 
2) Calculate change p-values using a signed Wilcoxon rank test (as recommended 
by Affymetrix) on the raw hybridization data for every pair-wise replicate 
comparison (Fig.3). The algorithm for calculating the p-values was rewritten by E. 
Oakeley to reduce the time complexity of the calculations from 2N to N3 
(N=number of oligonucleotides per transcript, typically 32). Any probe showing a 
change p-value of <0.003 was discarded. 
 
 
 
 
 
Fig.2 Screen shot 
of ChangeMaker. 
By clicking on 
the tickbox, 
the user 
selects the 
comparisons 
to be 
performed 
Fig.3 Schema representing an 
example of comparisons between 
two groups (A and B) each 
containing three replicates (1, 2, 
3). The algorithm will perform all 
the pairwise comparisons and 
generate nine separate lists 
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3) Once the lists of genes significantly changing for each comparison has been 
established, the lists are crossed together to determine whether each transcript 
shows a consistent change in multiple pair-wise comparisons. For example, in 
an experiment with three overlapping lists, four regions of intersection can be 
found, indicated in yellow and white on (Fig.4). These correspond to regions 
where the probes have been shown to change in 2/3 of the comparisons 
performed (in yellow) or in all of them (white). The program pulls these lists 
together and creates three main lists. The first one contains genes that change 
in all the replicates compared, the second contains genes that change in two 
thirds of replicates, and the final one contains all the probes that have changed 
in at least one of the replicates. Taken together, these lists constitute three 
different stringencies of analysis. The exercise is not trivial, since the number of 
overlapping regions increases exponentially with the number of lists to be 
analyzed. The number of overlapping regions corresponds to (2n–1)–n. Using 
the example described in (Fig.3), we obtain nine lists. This would correspond to 
502 overlapping regions for each condition analyzed, which excludes any 
possibility of performing this task manually. 
 
 
 
 
 
 
 
 
4) The resulting main lists are exported to Genespring, a statistical program used in 
the institute for microarray analysis. The lists are further divided into genes 
increasing or decreasing in relation to the baseline sample provided in the 
comparisons (Fig.5). 
Fig.4 Venn diagram 
showing an example 
of intersection 
between three lists 
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o Conclusion 
The ChangeMaker program provides a valuable tool for accelerating the analysis of 
microarray data using the raw oligonucleotide hybridizations, especially when dealing 
with replicates. The program does not consider fold change or expression level but 
simply patterns of variation based on the idea that if a single RNA class changes in 
concentration then all hybridizing targets should move in the same direction. More 
convertional analyses based on expression estimates may then be performed later 
using GeneSpring. The resulting gene lists are divided according to the direction and 
stability of the change observed, therefore allowing a certain degree of flexibility in the 
analysis of replicates.  
 
 
Fig.5 Screen shot of 
Genespring 6.1 showing the 
display of the lists resulting 
from the ChangeMaker 
program 
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MicroPlot 
o Introduction 
This program was designed as a web application to visualize microarray data.  
 
The analysis of microarrays can provide direct results but can also constitute a library 
of information, which can be used at a later timepoint. This information must therefore 
be easily accessible and not confined to users experienced in microarray analysis. This 
application has been programmed in ASP.Net language and makes use of 
the .netcharting© module. 
o Method 
I developed a web application which displays, upon request, a graph of the expression 
data of a selected gene. The first part of the program, the loader, creates a database 
containing the expression data and the standard error (in case replicates are present) 
of each transcript in the experiment. The data can be inserted into the loader as an 
Excel worksheet. Once the database has been created, it is possible to query the data 
through a web page. The user inputs the name of the gene, its symbol or the Affymetrix 
probeset ID (Fig.6A), and a list of the transcripts matching the specified criteria appears 
(Fig.6B). Upon selection of one of the genes, a chart is displayed showing the 
expression data and the standard error of each timepoint in each genotype (Fig.6C). 
 
The searches can also be performed using parameters on the web address. For 
example: http://<ServerName>/AllProbes.aspx?search=e2f1. This will direct the web 
page directly to the E2f1 expression data. This function becomes very useful for linking 
Excel spreadsheets to a graph output (Fig.6D). 
o Conclusion 
MicroPlot provides the possibility of viewing microarray expression data through a web 
page. It therefore allows the sharing of results between collaborators and other 
interested people, who may have no experience in microarray data analysis. 
Furthermore, it allows the generation of graphs which can be saved and pasted into 
other applications (the graphs of microarray data shown in this thesis were generated 
Page - 75  
 
 
using this program). Additional features could provide links to other databases to 
provide further data and insights in the gene being analyzed. 
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PromoterPlot 
 
PromoterPlot was designed with the aim of finding common regulatory regions between 
genes. Using microarray analysis it is possible to identify clusters of genes which are 
co-expressed. However, to date it is very difficult to determine if the genes obtained are 
regulated by the same mechanisms without prior knowledge of the transcription factors 
involved. Originally, PromoterPlot was designed as a tool to view the positioning of 
transcription factors on promoter sequences. The use of this program was then applied 
to another project by E. Oakeley, which aimed at finding common transcriptional factor 
motifs amongst genes. This led to the development of a pattern-finding algorithm that 
would find common patterns of transcription factors on promoters. This program was 
written in close collaboration with E. Oakeley. I was mostly involved in the creation of 
the graphical interface and the programming of the pattern-finding algorithm. The 
following manuscript, embedded in this thesis, relates the functioning of this software 
and shows its application on the study of the c-jun promoter. The microarray data used 
in the manuscript derives from experiments from Karsten Schimdt, a former fellow from 
Brian Hemmings' laboratory at the FMI. The program was developed as a web 
application in ASP.Net and Javascript.  
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ABSTRACT
PromoterPlot (http://promoterplot.fmi.ch) is a web-
based tool for simplifying the display and processing
of transcription factor searches using either the
commercial or free TransFac distributions. The input
sequence is a TransFac search (public version) or
FASTA/Affymetrix IDs (local install). It uses an intuit-
ive pattern recognition algorithm for finding similar-
ities between groups of promoters by dividing
transcription factor predictions into conserved triplet
models. To minimize the number of false-positive
models, it can optionally exclude factors that are
known to be unexpressed or inactive in the cells
being studied based on microarray or proteomic
expression data. The program will also estimate the
likelihood of finding a pattern by chance based on the
frequency observed in a control set of mammalian
promoters we obtained from Genomatix. The results
are stored as an interactive SVG web page on our
server.
INTRODUCTION
The initial objective of this work is to develop a viewing tool
to display the results of TransFac searches in a graphic form. In
this paper, we will describe a software tool we have developed
for combining expression data with promoter analysis.
Promoter analysis is a process that has historically been very
difficult to perform in higher eukaryotes (1). The first question
one must consider is how exactly to define a promoter? In
the context of this article, we will be using the definition that
the ‘core promoter’ should occupy a region 500 bp upstream of
the start of transcription (2). The challenge with this defini-
tion is how should we obtain the starts of transcription?
The variable and sometimes large 50-untranslated regions of
mammalian messages make any reference to the start of trans-
lation rather weak, and the poor sequence conservation
between starts (3) makes computer prediction a complex
and sometimes unreliable task. We purchased the promoter
resources for human, mouse and rat from Genomatix (http://
www.genomatix.de) which, as of spring 2004, contained
156 000 starts of transcription. Many of these had been
experimentally mapped using oligo capping technology (4).
Non-commercial resources also exist, most notably the Euka-
ryotic Promoter Database (http://www.epd.isb-sib.ch/) (5) and
the various genome sequence repositories.
There are two major schools of thought regarding promoter
analysis at the present time: first, the sequence-based approach
where short regions of sequence conservation between regu-
latory sequences are assembled in an attempt to predict regions
of micro-conservation that might be important in the control of
gene expression, e.g. the MEME motif discovery program (6)
which is a tool for discovering motifs in a group of related
sequences. MEME was one of the first such programs and it
strives to develop position-dependent probability matrices
for finding every possible letter at each position in a putative
pattern. The motifs found do not contain gaps but can be rather
short so that gaps are modeled by the occurrence of additional
motifs with un-conserved relative spacings. The size of these
motifs is automatically calculated by the program. One further
program is MotifSampler, which uses Gibbs sampling to
assign a probability distribution to the chance of finding appar-
ently conserved regions of sequence (7). These models do not
require any prior knowledge of the underlying biology and as
such it can be difficult to assess the mechanistic significance
of any pattern found (8), and even when sequence conservation
does occur it does not necessarily imply a conserved regulat-
ory function. The second major approach for promoter ana-
lysis is the knowledge-based search for known transcription
factor binding sites [reviewed in (9)]. This process relies on the
collection of information from the scientific literature about
the known binding sites from which a consensus target site
is estimated. This effort is largely the work of the German
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company Biobase GmbH (http://www.biobase.de) through
their Match program associated with the TransFac database.
Match provides extremely detailed reports of potential binding
sites in target sequences; however, the complexity of the
answers returned can be daunting. The challenge here is to
filter the data so that we can extract biologically useful models
for hypothesis formulation.
The objective of this work is to create a simple web applica-
tion which would use expression data or proteomics data to
filter the list of potential transcription factors predicted by
TransFac. We then developed an advanced pattern recognition
algorithm to extract patterns of conserved factors in the pro-
moters under investigation. Looking for single transcription
factors does not provide any measure of the significance of
findings above that given already in TransFac, instead modules
of multiple transcription factors in a defined order have been
shown to be critical for modulating the expression of genes
(10,11). Higher-order complexes may be considered as pairs,
triplets or greater numbers of factors in a module. Models
composed of three factors have already been shown to be
more selective than those of only two (12). Models with
even higher complexity are overly stringent and appear auto-
matically when searching for patterns of three. If multiple
overlapping binding sites are predicted for the same transcrip-
tion factor, these are concatenated in the display process into
a single big binding site. This helps to simplify the display
process without having a negative effect on the pattern search-
ing process. The output is presented as an interactive web page
using the Adobe SVG plug-in (Adobe Systems Inc., San Jose,
CA) for Internet Explorer. Our tool is distributed in two forms:
one for local installation, which can automate the TransFac
queries and promoter sequence extraction using in-house
information resources (source code available on request);
and a second which is freely available on the Internet
(http://promoterplot.fmi.ch). The input required for the
Internet-accessible version is a TransFac search, saved as a
text file, for your promoters. A free version of TransFac is
available from Biobase (http://www.gene-regulation.com/cgi-
bin/pub/programs/match/bin/match.cgi) which may be used
for this purpose.
DESIGN AND IMPLEMENTATION
PromoterPlot was developed as a web-based application. It
was designed using Visual Studio 2003 (ASP.NET 1.1) and
uses IIS as a web server (Microsoft Corporation, Redland,
WA). We recommend that users access our program using
Microsoft Internet Explorer 6 or later on the Windows
operating system as some users have reported problems
with other browsers. An Alchemi grid is used for processing
(www.alchemi.net).
Modeling factor patterns
Users can either use our tool as a simple TransFac viewer to
simply display the results of a TransFac search without further
processing or they can look for conserved potentially regulat-
ory modules within the promoters. To identify these conserved
modules, we developed a pattern-searching algorithm, which
works by scanning the promoter sequence for patterns com-
posed of three transcription factors (ABC). So as not to collect
patterns of very distant factors, which are less likely to interact
with each other, the patterns are selected according to the
maximum base pair distance between the first and the third
factor (C–A), in a user definable manner (default = 100 bp).
All of the patterns discovered in this way are collected in a
single list. The patterns which passed the following restrictions
are retained: (i) the same order of transcription factors; (ii) an
identical strand distribution of the factors; (iii) a conserved
spacing C–A and B–A with a user-defined ‘wobble’ for the
spacing conservation (default – 10 bp); and (iv) the pattern
must occur in more than one of the promoters analyzed
(default = 2). This process is summarized in Figure 1.
In our initial analysis, we found that the TransFac Match
search, using the ‘minimize false positives’ (FPs) setting, pre-
dicts on average one binding site every 20 bp. This high
stringency search is very tempting because it does not generate
Figure 1. Pattern finding with PromoterPlot. 1: Transcription factor binding
sites are predicted using the balanceFP/FNoption inTransFac. 2:Any factor for
which there is evidence that it is not actually expressed or active in the
tissue under investigation may be selectively removed from the analysis. 3:
Patterns of three factors with conserved internal spacings and consistent
binding strands which are found in two or more promoters are retained all
others are discarded. 4: The frequency of the predicted patterns is compared
with a database of mammalian promoters to estimate the probability of finding
the observed results by chance. 5: The results are displayed as an interactive
web page with matching genes from the database returned as Affymetrix IDs.
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large numbers of binding sites; however, comparisons with
published data are often not very good (13). Given that
transcription factors bind cooperatively in nature it may be
that sub-optimal sites are actually used in vivo which are
stabilized by interaction with other proteins in a complex (13),
but these sites often appear to be below the detection threshold
for an FP search. The lower stringency search options of
TransFac do a better job of finding the published interacting
factors, with the minimize false negatives (FNs) option pre-
dicting as many as five binding sites per nucleotide and the
balance FP/FN (SUM) option approximately one hit per nuc-
leotide (if all vertebrate matrices are included in the search).
However, when combined with our pattern discovery proced-
ure, the SUM option appears to give a good balance between
sensitivity and noise.
Clearly, the sequence of the promoter alone is unlikely
to be sufficient for the effective modeling of transcription
factor assembly because not every cell or developmental stage
will necessarily use the same transcription factors to control
expression in response to every possible stimulus (14). As not
every transcription factor is in an active state in every cell,
we can ask which transcription factors are expressed in the
cell and what protein modifications might influence their
activity? In our institute, we usually address this issue by
looking directly at the expression of all transcription factors
on Affymetrix microarrays. Any factor that is not expressed
in any of the steps of the experiment is unlikely to be present
to any significant quantity in regulatory complexes. Simil-
arly, information may also be available from proteomics
analysis of samples, which may reveal that certain factors
are in inactive phosphorylation states or otherwise excluded
from participation in the regulatory machinery. We decided
that such information, when available, represents a useful
resource for effective modeling and so users may optionally
provide a file containing the names of transcription factors or
TransFac matrix IDs which will be excluded from the ana-
lysis. Alternatively, during the course of expression data
mining, we often find that transcription factors themselves
are altered in their expression during an experiment. One
might hypothesize that some of these changing factors
have direct roles in the control of the other genes detected
and a question that we are often presented with is ‘can you
show me what ‘factor X’ might be doing to my promoters?’.
There are two solutions to this problem in our program: (i) if
users have specific factors of interest in mind then they can
provide a list of these and only patterns containing at least
one of the named factors will be displayed; (ii) users can
click on the factor names in the legend of the SVG display to
see those promoters that contain patterns including specific
factors.
Input data required
The potential inputs for PromoterPlot are TransFac result
files (internet version), FASTA files (local version only,
requires a local copy of TransFac) or Affymetrix IDs
(local version only, requires a local copy of TransFac and
a local promoter database). The FASTA headers should be
kept as short as possible, but can contain start of transcription
information in the following format: ‘>Some_Name’ then
‘#transcription_start_position:start_color#’. Multiple starts
can be supplied one after the other in this way. The final
characters can be a short description of the gene, for
example:
>12345 at#1985:gold#1951:silver#2001 :bronze#MyGene
In this example, it would draw a promoter for the gene
‘>12345_at:MyGene’ with a start colored ‘gold’ at position
1985, ‘silver’ at 1951 and ‘bronze’ at 2001. If you wish to
use other colors, then you can also enter base-10 RGB values
instead of the words in the format ‘R, G, B’. We recommend
that FASTA titles which do not use the above notation
should take the format ‘>MyGeneName’ and avoid using
non-alphanumeric characters.
Because the results are active web pages containing server-
side scripting, they are stored on our server for a maximum
of 72 h for ‘anonymous’ searches (users get a session ID which
they can use to access their data during this time). Users who
would like to keep results for longer periods are encouraged
to register (free) with a username and a password. Searches
stored in this way are kept until the user deletes them or
3 months have passed without access.
Display of results
The primary objective of the display is to make each factor
type visually distinct while retaining visual similarities
between factors with similar names. It is clear that the same
factor must always have the same appearance every time the
program is run. The factors are represented by a filled box
surrounded by a colored boarder (Figure 2). This two-color
approach makes the process of discrimination much easier
than with a single color. The fill colors are assigned automat-
ically by taking the name of the transcription factor (e.g.
STAT5) and converting the first three letters of the name
into their corresponding ASCII values to give the red,
green and blue color channels. If the name has fewer than
three characters, then the missing characters are replaced by
the ASCII code 00. The border color is generated in the same
way but now the dominance is reversed so that the color is
defined by the ASCII values of the final three characters of
the name in the order blue, green and red. Thus, the border
colors enable us to visually distinguish factors with very
similar names.
The results are displayed in a web page that is composed of
three frames: analysis, legend and output. Two viewing modes
Figure 2. The start(s) of transcription are represented by circles colored gold,
silver or bronze. Each factor is colored according to its name with the fill color
based on the name stem and the border color based on the name ending. The
factors and promoters are clickable and clicking provides information about
pattern groups, binding sites and other genes which share the same patterns.
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exist: the first mode (pattern view) displays only the patterns
discovered by the pattern-finding algorithm. Clicking on a
factor or its corresponding entry in the legend will display
all of the patterns containing that factor. Additionally, clicking
on the box at the 50 end of each promoter will display all of the
patterns found in the selected sequence in any other promoter.
The second mode (factor view) displays the individual tran-
scription factors (optionally even those that are not members
of patterns). Clicking on a factor will display the location of
that factor in all of the promoters. In addition, it will provide
the target binding site sequences and positions of these factors
in the output window. Thanks to the SVG plug-in, it is possible
to zoom and pan the analysis window, facilitating the display
of large numbers of sequences. All of the results are stored in a
password-protected user folder on our server. In the event
that a pattern query takes a very long time to complete, it
will continue to run on our server even if the web browser
is closed and users may log back in at a later date to view
their results.
Assessing the specificity of the results
We have purchased the sequences of 156 000 mammalian
promoters from Genomatix. When patterns are predicted by
the program, their frequency of occurrence in the test sequence
is calculated and compared with their frequency in the control
database. If we define a null hypothesis that there is no dif-
ference between the two frequencies, then we can test this
using a Chi-square test with one degree of freedom (15).
Each pattern has a vertical pin associated with it which is
clickable. Moving the mouse over the pin brings that pattern
to the foreground and makes the others translucent. Clicking
on a pin hides all patterns except for selected one and displays
the Affymetrix IDs for any of the mammalian promoters from
the database which also contain this pattern. The color of the
pin indicates the Chi-square result. Those patterns that fail the
test have red pins, patterns that pass with a P-value <0.05 have
green pins and those that pass with a P-value <0.01 have blue.
To partially compensate for small numbers of test promoters,
we perform a Yates’ correction for discontinuity to reduce the
risk of type I errors. Clicking on a gene shows the Affymetrix
IDs for all database genes with multiple conserved patterns.
DISCUSSION
Here, we present a new bioinformatic tool (PromoterPlot)
for automating the extraction of promoter patterns from
microarray-based expression data. Binding sites are predicted
using Biobase’s ‘Match’ program from the TransFac suite
(16). The pattern prediction process may be filtered to exclude
factors that are not believed to be active in the experiment. The
patterns identified are displayed in a simple interactive web-
based graphical interface and stored on the server for future
use in a password-protected user directory. We feel that this
may be a useful application for visualizing promoter compar-
isons and to assist in the identification of regions of potential
interest before engaging in time-consuming biochemical
characterization. The database hits predicted are also useful
for validation. The program may be accessed online at http://
promoterplot.fmi.ch.
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Appendix A 
 
List of  candidate genes derived from microarray comparison of S6/flox and ΔS6/flox 
mouse livers at different time points after hepatectomy. The list is divided by timepoints, 
from 0 to 40.hours. Negative fold changes represent situations in which the ΔS6/flox 
showed a value superior to the S6/flox. 
 
 
Time 0 ProbeSetID GeneSymbol FoldChange ChangePValue 
 93987_f_at 3110001N18Rik 3.23 5.74E-04 
 93536_at Bax -1.86 7.47E-03 
 96020_at C1qb 1.73 1.12E-03 
 161968_f_at Ccr5 2.52 6.22E-03 
 94939_at Cd53 1.50 6.59E-03 
 93445_at Cd5l 2.45 9.98E-04 
 94881_at Cdkn1a -3.87 1.02E-03 
 98067_at Cdkn1a -1.91 3.26E-03 
 103284_at Cyp8b1 1.74 6.68E-03 
 160265_at Eif5 -1.50 9.61E-03 
 101587_at Ephx1 -1.81 1.38E-03 
 100050_at Idb1 -1.81 2.19E-03 
 98110_at Mdm2 -1.57 1.07E-03 
 97497_at Notch1 -1.69 1.88E-03 
 98056_at Phlda3 -1.83 3.22E-03 
 96662_at Ppap2b 1.83 8.48E-03 
 101577_at Rps6 21.43 6.79E-05 
 104248_at Ssr3 1.50 4.80E-03 
 104249_g_at Ssr3 1.69 1.05E-03 
 96426_at Tmsb4x 1.50 2.75E-03 
 100397_at Tyrobp 1.51 4.56E-03 
Time 20 ProbeSetID GeneSymbol FoldChange ChangePValue 
 102807_at 9230112O05Rik 1.64 3.80E-03 
 96058_s_at Aldh2 -1.65 2.82E-03 
 104072_at Apcs -1.92 3.06E-03 
 93536_at Bax -1.58 1.36E-03 
 98562_at C1qa 2.28 2.32E-04 
 96020_at C1qb 2.33 1.39E-03 
 92223_at C1qg 2.28 1.46E-04 
 103016_s_at Cd68 1.79 5.66E-03 
 103334_at Crcp -1.68 5.02E-04 
 104354_at Csf1r 1.57 3.69E-03 
 100059_at Cyba 1.54 6.67E-03 
 97013_f_at Cyba 1.54 8.20E-03 
 102879_s_at Fcgr1 1.50 1.54E-03 
 99148_at Fh1 -2.02 1.28E-04 
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 92217_s_at Gp49b 1.52 5.08E-03 
 92222_f_at H2-Q1 2.67 2.12E-05 
 98467_at Itih4 -1.69 7.16E-04 
 104093_at Lsp1 1.53 6.24E-03 
 94425_at Ly86 1.51 9.34E-04 
 102974_at Marco 2.24 6.89E-03 
 101468_at Pfc 1.92 2.27E-04 
 98056_at Phlda3 -2.29 9.59E-03 
 102013_at Rdh6 -1.69 1.96E-03 
 98915_at Rnf149 -1.52 4.77E-03 
 101577_at Rps6 17.79 5.40E-04 
 92858_at Slpi 1.73 7.17E-03 
 100397_at Tyrobp 2.19 6.12E-03 
 92558_at Vcam1 1.56 1.37E-03 
Time 30 ProbeSetID GeneSymbol FoldChange ChangePValue 
 102091_f_at --- -1.59 2.45E-03 
 99849_at --- -1.79 3.81E-03 
 96348_at 0610039C21Rik -2.27 1.78E-03 
 98033_at 1100001H23Rik 1.68 8.84E-03 
 95409_at 1110019J04Rik -1.93 2.10E-03 
 96086_at 1110031B06Rik 1.96 9.04E-03 
 160266_r_at 1110064N10Rik -1.85 3.80E-03 
 98594_at 1190002N15Rik 1.98 2.01E-03 
 160676_at 1810012N18Rik -1.80 5.76E-03 
 95518_at 1810015C04Rik -4.66 3.74E-03 
 96122_at 2310016A09Rik 1.93 9.00E-03 
 160283_at 2410005K20Rik -1.85 3.24E-03 
 97866_at 2510049I19Rik 1.88 3.90E-03 
 103010_at 2610005L07Rik -1.70 3.48E-03 
 101962_at 2610007K22Rik 1.88 9.52E-03 
 102385_at 2610318G08Rik -1.70 5.30E-05 
 98973_at 2610318G08Rik -2.15 3.85E-03 
 96925_at 2810024B22Rik 1.98 2.82E-04 
 103071_at 2810429C13Rik 1.80 7.55E-05 
 93987_f_at 3110001N18Rik 2.45 1.35E-03 
 93437_f_at 4632419I22Rik 1.62 5.52E-03 
 103389_at Aass -1.64 6.20E-03 
 101515_at Acox1 1.93 8.38E-03 
 92796_at Akp2 -3.77 3.47E-04 
 102114_f_at Angptl4 -1.77 2.55E-03 
 96792_at Apob 1.97 5.88E-03 
 104328_at Aqp9 2.89 7.95E-03 
 160371_at Arl6ip1 1.98 4.39E-03 
 103697_at AW061234 2.27 7.93E-03 
 160384_at Bat1a -1.74 2.28E-03 
 101582_at BC003262 -1.97 1.06E-03 
 103695_f_at C330007P06Rik 1.74 8.23E-03 
 93741_at C87860 -1.87 1.07E-03 
 93445_at Cd5l 3.02 9.83E-03 
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 100128_at Cdc2a 2.25 4.86E-03 
 94881_at Cdkn1a -5.12 5.22E-03 
 101088_f_at Cnbp1 -2.04 7.79E-03 
 93550_at Csrp2 1.53 6.37E-03 
 102847_s_at Cyp2a4 -3.42 5.66E-03 
 102701_at Cyp2b20 -3.66 3.77E-03 
 160957_at D12Ertd7e 1.58 1.19E-03 
 94502_at D13Wsu50e -1.64 2.93E-04 
 98071_f_at Dck 1.97 4.56E-03 
 93843_at Dhrs1 1.82 2.29E-03 
 102797_at Dhrs3 1.73 3.30E-05 
 160203_at Dnajc9 1.68 2.47E-03 
 100535_at E130105L11Rik -1.93 7.45E-03 
 104666_at E430039K05Rik -1.74 7.24E-03 
 97411_at Ect2 2.29 1.42E-03 
 160265_at Eif5 -2.39 4.03E-04 
 94393_r_at Elovl2 1.88 1.14E-03 
 97317_at Enpp2 -2.39 7.46E-03 
 101587_at Ephx1 -1.62 6.38E-03 
 98076_at Erp29 1.71 3.74E-03 
 160451_at Etf1 -1.67 8.86E-04 
 98608_at Etf1 -2.02 4.50E-03 
 100494_at Fgf1 2.06 4.95E-03 
 92808_f_at Fkbp4 2.51 3.83E-03 
 92697_at Foxa1 1.77 6.51E-03 
 103036_at G22p1 1.98 7.99E-03 
 96336_at Gatm 1.76 3.82E-03 
 103498_at Gcgr 1.51 1.95E-03 
 97819_at Gsto1 -1.64 9.26E-03 
 99180_at Gtpbp4 -1.52 4.10E-03 
 96710_at H2av 1.93 9.34E-03 
 103534_at Hbb-b1 5.80 7.23E-03 
 92590_at Hmgcs2 1.96 3.29E-03 
 160104_at Hsd3b7 2.04 1.39E-03 
 96594_at Hspa4 3.58 2.00E-03 
 96172_at Ian1 1.54 4.92E-03 
 160092_at Ifrd1 -4.54 7.05E-04 
 97987_at Igfals 2.65 2.83E-03 
 92739_at Ivl -1.94 2.31E-03 
 99632_at Mad2l1 1.77 1.00E-03 
 100062_at Mcm3 1.90 6.86E-03 
 160496_s_at Mcm3 2.27 2.59E-03 
 93041_at Mcm4 2.24 9.41E-04 
 102699_at Mx2 -3.24 5.29E-04 
 98587_at Nap1l1 2.10 6.64E-03 
 103907_at Nedd4l -1.53 7.49E-03 
 92569_f_at Nol5 -1.91 9.97E-03 
 97824_at Nola2 -1.73 9.54E-03 
 101002_at Oazin 2.32 7.79E-03 
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 100737_at Onecut1 1.77 3.46E-03 
 99056_at Pcbd 1.56 7.16E-03 
 101065_at Pcna 2.03 3.83E-03 
 100554_at Pdlim1 -1.82 1.45E-04 
 93619_at Per1 -1.52 2.57E-03 
 99469_at Pex6 1.58 4.31E-03 
 97965_at Pla2g6 -2.22 3.81E-03 
 102663_at Plaur -1.50 1.90E-03 
 103207_at Pola1 1.86 5.96E-04 
 99019_at Por -1.58 4.73E-03 
 93485_at Ptprd 1.52 1.65E-03 
 160197_at Pycrl 1.75 6.18E-03 
 92659_at Rapgef4 -1.59 2.96E-03 
 104476_at Rbl1 1.80 7.14E-03 
 160759_at Rfc2 1.78 2.97E-03 
 103418_at Rfc4 1.88 7.67E-04 
 161787_f_at Ris2 1.78 1.39E-03 
 94024_at Ris2 1.57 8.75E-03 
 93782_at Rnf4 -1.89 8.22E-03 
 101889_s_at Rora -1.89 5.13E-03 
 98081_at Rpo1-3 -1.72 2.34E-03 
 101577_at Rps6 22.50 6.71E-05 
 98950_at Rragc -1.53 8.69E-03 
 100612_at Rrm1 1.63 0.00665121 
 100985_at Siah1a -1.57 3.43E-03 
 98596_s_at Siat9 -3.28 5.38E-03 
 100916_at Slc22a1 1.77 3.24E-04 
 104560_at Slc25a28 -1.56 3.32E-03 
 94797_at Slc26a1 3.30 8.24E-03 
 101877_at Slc31a1 2.09 5.37E-03 
 99133_at Slc3a2 -2.14 1.12E-03 
 97309_at St13 1.79 9.71E-03 
 96326_at Tat -1.62 1.67E-03 
 102354_at Tcf19 1.78 7.05E-03 
 102315_at Tex292 -1.93 6.56E-03 
 93728_at Tgfb1i4 2.39 7.02E-03 
 103794_i_at Timd2 2.26 5.14E-03 
 101964_at Tkt -1.55 2.98E-03 
 93236_s_at Tyms 1.63 4.49E-03 
 93237_s_at Tyms-ps 1.55 4.69E-04 
 160605_s_at Usp38 -1.52 6.15E-03 
 95709_at Vkorc1 1.54 8.89E-03 
 99963_at Zfp101 1.69 6.10E-03 
 103753_at Zzz3 -1.64 9.31E-03 
Time 40 ProbeSetID GeneSymbol FoldChange ChangePValue 
 96156_at 1110008H02Rik -2.17 5.70E-03 
 95409_at 1110019J04Rik -1.81 4.33E-03 
 95690_at 1110030L07Rik -1.61 1.82E-03 
 104670_at 1700065A05Rik 1.59 4.67E-03 
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 103027_at 1810030O07Rik -1.54 6.26E-04 
 95406_at 1810037I17Rik 1.70 9.38E-03 
 104588_at 1810073K19Rik -1.91 4.85E-06 
 160569_at 2310008M10Rik 1.98 1.70E-04 
 161332_f_at 2610036L13Rik 1.52 6.29E-03 
 102385_at 2610318G08Rik -1.52 2.87E-03 
 100955_at 2700084L22Rik 2.76 2.85E-03 
 96016_at 2700094K13Rik 2.97 4.86E-03 
 93441_at 2700099C18Rik 1.81 5.13E-03 
 104423_at 2810047L02Rik 2.09 3.11E-04 
 100116_at 2810417H13Rik 2.57 1.48E-03 
 160279_at 4930588M11Rik -1.68 9.90E-03 
 95753_at A730011O11Rik 2.36 2.08E-03 
 104578_f_at Actn1 1.69 2.38E-03 
 104579_r_at Actn1 1.54 1.23E-03 
 98999_at Adsl -1.62 8.92E-03 
 95378_at AI842396 -1.58 6.78E-04 
 160090_f_at Aldo1 -1.83 1.64E-03 
 96784_at Anln 2.82 3.59E-03 
 160371_at Arl6ip1 1.97 4.03E-03 
 104745_at Arl6ip2 -2.06 2.74E-04 
 93798_at Atp1a1 -1.59 2.54E-04 
 93984_at Atpi 1.64 6.72E-04 
 98469_at Aurkb 1.65 3.60E-03 
 100944_at AW112010 1.97 1.94E-03 
 98545_at Bcap37 -1.86 4.87E-03 
 101521_at Birc5 2.76 6.03E-04 
 102976_at Brca1 1.60 8.94E-03 
 104097_at Bub1 1.61 1.24E-03 
 160585_at Bxdc1 -1.59 9.92E-03 
 102773_at Car8 1.61 4.65E-03 
 104259_at Cbx5 1.86 7.36E-03 
 99186_at Ccna2 1.89 8.42E-05 
 160159_at Ccnb1 5.84 1.53E-03 
 94294_at Ccnb2 3.21 1.90E-04 
 96319_at Cdc20 5.70 1.08E-04 
 94048_at Cdc34 -1.58 4.36E-03 
 103821_at Cdc6 2.63 5.08E-04 
 94217_f_at Cdca3 2.03 7.25E-05 
 160638_at Cdkn2c 1.97 8.78E-05 
 94971_at Cdkn3 1.53 1.17E-03 
 96346_at Cdo1 -1.68 3.76E-03 
 100616_at Cenpa 2.01 5.56E-04 
 101538_i_at Ces3 2.43 9.19E-03 
 104322_at Ckap2 2.22 3.99E-04 
 97468_at Cks1 2.79 6.28E-03 
 101093_at Col4a1 -1.69 7.50E-03 
 94784_at D030034H08 1.70 1.23E-03 
 160310_at D19Bwg1357e -1.82 7.85E-03 
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 97295_at D4Ertd421e 2.64 2.86E-03 
 93257_at Ddx1 -1.53 1.15E-03 
 98489_at Dlg7 1.60 5.69E-03 
 97880_at Dlst -1.66 1.89E-03 
 96680_at Dnajb9 2.24 1.92E-03 
 100535_at E130105L11Rik -2.00 7.55E-03 
 97205_at Eif3s1 -2.01 4.35E-03 
 160265_at Eif5 -3.42 6.66E-05 
 99917_at Ezh2 1.99 9.80E-03 
 94075_at Fabp1 1.81 1.58E-03 
 97327_at Fen1 4.46 4.39E-03 
 160648_at Fignl1 2.86 2.89E-03 
 99546_at Fkbp2 1.53 2.40E-03 
 160069_at Gmnn 1.71 2.81E-03 
 103808_at Golga5 -1.72 4.54E-03 
 93019_at H2afx 6.48 6.55E-03 
 101954_at H2afz 3.66 2.10E-03 
 96710_at H2av 2.72 4.48E-04 
 97895_f_at Hat1 1.72 1.28E-03 
 162457_f_at Hba-a1 3.52 3.12E-03 
 94781_at Hba-a1 11.60 5.00E-03 
 101869_s_at Hbb-b1 13.31 6.06E-03 
 94805_f_at Hist1h2ac 2.24 1.22E-03 
 93023_f_at Hist2h3c2 1.72 7.43E-03 
 93095_at Hmgb1 1.54 9.93E-03 
 93250_r_at Hmgb2 3.34 3.31E-03 
 94795_at Hsd3b4 4.89 7.94E-03 
 93752_at Iars -1.71 8.03E-03 
 160092_at Ifrd1 -4.69 1.95E-03 
 95034_f_at Ipo4 -1.78 9.18E-03 
 160501_at Kif20a 3.33 1.49E-03 
 161856_f_at Kif20a 1.60 1.26E-04 
 95118_r_at Kif22 1.78 4.61E-03 
 160755_at Kif2c 2.57 1.72E-04 
 97903_at Leng5 1.54 9.22E-04 
 160517_at Lmnb1 2.03 2.91E-03 
 99632_at Mad2l1 4.39 3.90E-03 
 95721_at Mapkapk2 -1.87 2.45E-03 
 160496_s_at Mcm3 2.53 3.76E-03 
 100156_at Mcm5 5.30 6.37E-03 
 104033_at Mgea6 -1.60 8.82E-04 
 93342_at Mki67ip -1.63 4.00E-03 
 100885_at Nek2 3.02 3.63E-03 
 161000_i_at Nusap1 3.91 4.50E-03 
 100720_at Pabpc1 -1.75 2.69E-04 
 93615_at Pbx3 1.73 8.10E-03 
 93308_s_at Pcx -1.55 3.54E-03 
 98102_at Pdha1 -1.80 5.28E-04 
 98056_at Phlda3 -2.01 1.04E-03 
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 99926_at Pigr 2.00 7.03E-03 
 101350_g_at Plk1 1.64 9.02E-03 
 93099_f_at Plk1 2.15 1.70E-03 
 98996_at Plk4 2.35 5.35E-03 
 99019_at Por -1.70 4.51E-03 
 94915_at Ppib 1.60 6.34E-03 
 93495_at Prdx4 1.93 1.17E-03 
 97560_at Psap 1.62 4.45E-03 
 94953_at Racgap1 1.60 2.70E-03 
 93676_at Rad51ap1 1.52 4.81E-03 
 104476_at Rbl1 1.94 1.79E-03 
 94024_at Ris2 1.92 6.58E-04 
 101577_at Rps6 16.29 1.10E-04 
 100612_at Rrm1 2.26 2.31E-03 
 102001_at Rrm2 7.54 5.83E-03 
 93548_at Sec61b 1.84 5.31E-03 
 103345_at Spna2 -1.58 4.03E-03 
 92639_at Stk6 5.10 1.16E-03 
 97238_at Tacc3 1.70 1.93E-03 
 102354_at Tcf19 2.43 9.93E-03 
 104601_at Thbd -1.97 5.90E-03 
 96081_at Tk1 2.01 9.78E-03 
 92782_at Tmpo 1.55 3.23E-03 
 99578_at Top2a 2.60 1.50E-03 
 100343_f_at Tuba1 1.68 1.29E-03 
 98759_f_at Tuba2 1.91 1.26E-03 
 101543_f_at Tuba6 1.73 4.19E-04 
 93237_s_at Tyms-ps 2.38 2.61E-03 
 99564_at Uhrf1 2.19 3.02E-03 
 160321_at Zfp216 -1.68 6.40E-04 
 101890_f_at Zrf2 -1.86 5.29E-03 
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